ubc department of medicine awards by division for … · awards by division for 2002-2003 division...

UBC DEPARTMENT OF MEDICINE

AWARDS BY DIVISION FOR 2002-2003

Division Researcher Type Award Sponsoring Agency Title

Allergy/Immunology Schellenberg, Robert Grant 20,325 BC Lung: Research Grant Effects of Tone on Human Airway Smooth Muscle Contractile Responses: Relevance to Obstructive Lung Disease.

Allergy/Immunology Schellenberg, Robert Grant 3,500 Various SourcesAllergy/Immunology Schellenberg, Robert Clinical Trial 1,616 AstraZeneca Canada Inc Efficacy and safety of budesonide/formoteral (Symbicort) Turbuhaler as single therapy in patients

with mild-moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort Turbuhaler as maintenance therapy, both completed with Bricanyl

Cardiology Bernstein, Victoria Grant 70,842 Various pharmaceutical companies

Cardiology Research

Cardiology Bernstein, Victoria Clinical Trial 8,333 Novartis Pharmaceuticals Canada Inc

Multinational multi centre double blind, randomized active controlled parallel group study comparing the efficacy and safety of long term treatment with valsartan, captopril and their combination on mortality in high risk patients after mt

Cardiology Bernstein, Victoria Clinical Trial 16,943 Hamilton Health Sciences Corporation

ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

Cardiology Bernstein, Victoria Clinical Trial 15,399 Duke University Medical Centre STICH: Surgical Treatment for Ischemic Heart Failure

Cardiology Bernstein, Victoria Clinical Trial 4,640 Medical Research Council Heart Outcomes Prevention Trial (HOPE)Cardiology Bernstein, Victoria Clinical Trial 22,652 Knoll Pharmaceuticals PEACE - Prevention of Events with Angiotensin Converting Enzyme InhibitionCardiology Bernstein, Victoria Clinical Trial 55,508 Pfizer Canada Inc. IMAGINE - Ischemia Management with Accupril post bypass graft via inhibition of converting

enzyme (IMAGINE): An on evaluation of the effect of 12 to approximately 24 months treatment with Quinapril 40 mg QD post CABG surgery Ismetic events.

Cardiology Bernstein, Victoria Clinical Trial 29,961 Eli Lilly Canada Inc. Ruth Study, Raloxifene Hydrochloride or placebo in postmenopausal women at risk for major cardiovascular events.

Cardiology Bernstein, Victoria Clinical Trial 10,966 Astra Pharmaceuticals CANDESARTAN CILEXETIL (Candesartan) heart failure assessment of reduction in mortality and morbidity (CHARM) 3 protocols AHS-0003 0006 0007

Cardiology Buller, Christopher Contract 1,873 Guidant Corporation In Vivo Evaluation of the WTO guide wire, a Non-Glp StudyCardiology Buller, Christopher Grant 30,000 VHHSC Clinical Investigator

AwardTesting the Late Open Artery Hypothesis.

Cardiology Buller, Christopher Grant 23,628 NIH (US): Research Grant Total Occlusion Study of Canada-2 (TOSCA-2) An Angiographic Substudy of the Occluded Artery Trial (OAT)

Cardiology Buller, Christopher Clinical Trial 3,266 Amersham Life Sciences Inc. A Double-Blind Randomized Comparator Study Comparing the Renal Effects of Visipaque 320 (iodixanol) vs Optiray 320 (ioversol) in Chronic Stable Renal Failure Subjects Undergoing Coronary Angiography

Cardiology Buller, Christopher Clinical Trial 135,567 The Medicines Company REPLACE-2: Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, part 2-Protocol:TMC-BIV-01-03

Cardiology Buller, Christopher Clinical Trial 44,533 Proctor & Gamble Canada A randomized double blind placebo controlled study of two Intravenous dosing regimens of h5G1.1-scFv in patients with acute myocardial infarction undergoing percutaneous transluminal coronary angioplasty reperfusion therapy

Cardiology Carere, Ronald Grant 11,375 National Heart, Lung and Blood Institute

Open Artery Trial (OAT)

Cardiology Carere, Ronald Clinical Trial 8,400 Novoste Corporation The Beta-Cath(TM) System Trial

UBC Department of Medicine 58 Annual Report 2002




Cardiology Carere, Ronald Grant 3,000 Biocompatibles A prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the BATIMASTAT loaded BioDivYsio(R) PC coated SV stent versus balloon angioplasty for the reduction of restenosis in small coronary arteries

Cardiology Carere, Ronald Clinical Trial 307 Duke University Medical Centre ESPRIT: Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (98-025)

Cardiology Carere, Ronald Grant 3,470 Open Artery Trial (OAT II)Cardiology Carere, Ronald Agreement 21,142 Medical Research Council Clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) Trial

Cardiology Chan, Sammy Grant 80,000 H&SFBC: Research Lipid lowering effects on LDL subclasses and endothelial functionCardiology Chan, Sammy Clinical Trial 24,443 Pfizer Canada Inc. Modulation of arterial reactivity using Amlodipine and Atorvastatin measured by ultrasound

examination STUDY A0531006Cardiology Fung, Anthony Clinical Trial 400 Sanofi Canada Inc CURE - A phase III randomized, double blind, parallel group clinical trial of clopidogrel versus

placebo in patients with an acute coronary syndrome (unstable angina or myocardial infarction without st segment elevation)

Cardiology Gin, Kenneth Clinical Trial 12,665 Pharmacia (Canada) Inc. IE3 99-02-035, Double blind, randomized, placebo controlled trial evaluating the safety and efficacy of Eplerenone in patients with heart failure following acute Myocardial Infarction.

Cardiology Gin, Kenneth Clinical Trial 8,300 AstraZeneca Canada Inc SPORTIF V Efficacy and safety study of the oral direct Thrombin Inhibitor H 376/95 compared with dose-adjusted Warfarin (Coumadin) in the prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation

Cardiology Hamburger, Jaap Clinical Trial 1,152 Boston Scientific Corporation TAXUS II: Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent.

Cardiology Hamburger, Jaap Clinical Trial 15,404 Atherogenics, Inc. Safety and efficacy of AGI-1067 as an agent to prevent post angioplasty restenosis and coronary atherosclerosis progression (CART II)

Cardiology Hamburger, Jaap Clinical Trial 11,533 Boston Scientific Corporation FILTERWIRE(TM) during transluminal intervention of saphenous vein grafts (SVG)Cardiology Hamburger, Jaap Grant 4,023 Advanced Stent Technologies Inc A non GLP study using the AST SLK-View stent in an acute porcine coronary artery model

Cardiology Humphries, Karin Grant 49,990 MSFHR: Career Investigator Program C1-SCH-67(01-2)

Establishment Grant: Secondary prevention - the gap between evidence and practice


Secondary prevention - the gap between evidence and practice


Matching Establishment Grant: Secondary prevention - the gap between evidence and practice

Cardiology Humphries, Karin Grant 60,172 CIHR: Operating Grant MOP 57884

Secondary prevention - the gap between evidence and practice

Cardiology Humphries, Karin/ Carere & Thompson

Grant 62,500 CIHR/HSFC CCORT Project

Cardiology Ignaszewski, Andrew Clinical Trial 1,530 Bristol-Myers Squibb Company (Canada)

Omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) Protocol CV137-068

Cardiology Ignaszewski, Andrew Clinical Trial 48,353 Parke-Davis Pharmaceuticals The effect of LDL-cholesterol lowering beyond currently recommended minimum targets on coronary heart disease (CHD) recurrence in patients with per-existing CHD

UBC Department of Medicine Page 159 Annual Report 2002




Cardiology Ignaszewski, Andrew Clinical Trial 14,782.00 Sanofi-Synthelabo Canada Inc. (AQUAVIT) A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the effects of vasopressin V2 receptor antagonist (SR121463B) on clinical improvement in patients with severe chronic heart failure

Cardiology Ignaszewski, Andrew Clinical Trial 6,032.00 Amgen, Inc. A double-blind, randomized, placebo-controlled, multicentre study to assess the impact of subcutaneous (SC) Darbepoetin Alfa treatment on exercise tolerance in subjects with symptomatic congestive heart failure (CHF) and anemia

Cardiology Jue, John Clinical Trial 5,625.00 Servier Canada Echo Research AccountCardiology Jue, John Contract 15,750.00 Various Sources The Synergy Trial: A Prospective, Randomized, Open-Label, Multicentre Study in Patients

Presenting with Acute Coronary Syndromes (ACS).Cardiology Jue, John Clinical Trial 34,270.00 Aventis Pharmaceuticals Inc. A multi-centre, six-month, double-blind, placebo-controlled, parallel-group design clinical study to

assess the efficacy and safety of a daily oral dose of 125mg of Azimilide Dihydrochloride for the prophylactic treatment of atrial fibrilli

Cardiology Kerr, Charles Contract 22,500 Various Pharmaceuticals Study of ArrhythmiasCardiology Kerr, Charles Contract 600 Proctor & Gamble Canada The Canadian Registry of Atrial Fibrillation IIb - A prospective study of the natural history of new

onset atrial fibrillationCardiology Kerr, Charles Clinical Trial 29,213 Procter & Gamble, Canada A multi-centre, six-month, double-blind, placebo-controlled, parallel-group design clinical study to

assess the efficacy and safety of a daily oral dose of 125mg of Azimilide Dihydrochloride for the prophylactic treatment of atrial fibrilli

Cardiology Kerr, Charles Clinical Trial 14,400 Procter & Gamble, Canada A six month multi-center, double-blind, placebo-controlled, parallel-group design clinical study to assess the efficacy and safety of a 125mg daily oral dose of Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients

Cardiology Kerr, Charles Clinical Trial 14,000 Solvay Pharmaceuticals A multi-center, double-blind, randomized, placebo-controlled, sequential ascending dose groups study to evaluate the efficacy and safety of intravenous Tedisamil in the rapid conversion to normal sinus rhythm in patients with atrial fibrilli

Cardiology Kerr, Charles Clinical Trial 410 Various Sources Cardiology Trust FundCardiology Kerr, Charles Clinical Trial 18,282 AstraZeneca Canada Inc Efficacy and safety study of the oral direct thrombin inhibitor H376/95 compared with dose-adjusted

Warfarin (Coumadin(R)) in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V)

Cardiology Mancini, John Contract 175,134 Otsuka America Pharmaceutical Inc

CREST: Cilostazol for RESTenosis (CREST) Trial

Cardiology Mancini, John Contract 5,625 Various Pharmaceutical TARGET: The Athersclerosis Research Group of B.C.Cardiology Mancini, John Grant 367,992 Various Sources Carotid studiesCardiology Mancini, John Clinical Trial 30,978 Pfizer Inc. PREVENT: Prospective, Randomized Evaluation of the Vascular Effects of Norvasc Trial - Protocol

L-0200Cardiology Mancini, John Agreement 1,645 National Institutes of Health Occluded Artery Trial (OAT) - Angiographic CoreCardiology Mancini, John Clinical Trial 399,605 MRC: Clinical Trials Clinical outcomes utilizing revascularization and aggressive drug evaluation (courage)Cardiology Thompson, Christopher Clinical Trial 51,145 Procter & Gamble, Canada A randomized, double-blind, placebo-controlled study of two intravenous dosing regimens of

h5G1.1-scFv in patients with acute myocardial infarction undergoing percutaneous transluminal coronary angioplasty (PTCA) reperfusion therapy (CARDIN

Cardiology Thompson, Christopher Clinical Trial 4,427 Thoratec Laboratories Corporation

Clinical study of the Thoratec Aria coronary artery bypass grafta one-sided equivalency study to demonstrate that the Thoratec ARIA is substantially equivalent or better than marginal quality autologous vessel graft (the control group)





Cardiology Tungs, Stanley Clinical Trial 2,000 St. Jude Medical Inc. Sensitivity and Specificity of Morphology Discrimination: A Prospective StudyCardiology Webb, John Clinical Trial 210 Boston Scientific Corporation NIR ultimate gold bilded equivalency trial - nugget studyCardiology Webb, John Clinical Trial 39,859 Boston Scientific Corporation TAXUS II: A double-blind, controlled, study of the safety and performance of the NIRx(TM)

Paclitaxel-coated conformer coronary stentCardiology Webb, John Clinical Trial 4,941 Boston Scientific Corporation SYMBIOT III: A prospective randomized trial evaluating the Symbiot III covered stent system in

saphenous vein graftsCardiology Webb, John Clinical Trial 15,621 PercuSurge Inc. Enhanced myocardial efficacy and recovery by aspiration of liberalized debris (EMERALD) P02-

0040Cardiology Webb, John Clinical Trial 2,917 Cor Therapeutics, Inc. Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)Cardiology Webb, John Clinical Trial 100 Aventis Pharmaceuticals Inc. A prospective, randomized, open-label, multicenter study in patients presenting with acute coronary

syndromes (SYNERGY)Cardiology Webb, John Clinical Trial 4,000 NMT Medical, Inc. Evaluation of the CardioSEAL(R) STARFlex(TM) septal occlusion system in patients with a stroke

and/or transient ischemic attack (TIA) due to presumed paradoxical embolism through a patent formaen ovale

Cardiology Webb, John Clinical Trial 3,331 Cardiac Assist Technologies Evaluation of short term use of the AB-180 Percutaneous Transseptal Ventricular Assist (PTVA) System for cardiogenic shock

Cardiology Webb, John Clinical Trial 218,305 PharmaSonics Inc Sound Wave Inhibition of Neointimal Growth (SWING)Cardiology Webb, John Clinical Trial 8,637 PharmaSonics Inc SPLASH - Sonotherapy Prevention of Late Arterial In-Stent HyperplasiaCardiology Webb, John Clinical Trial 31,500 MDMI Technologies, Inc. The MDMI Rapid-Exchange PTCA Catheter: Safety and Effectiveness StudyCardiology Webb, John Clinical Trial 57,323 The Medicines Company A randomized evaluation of PCI linking Angiomax to reduced clinical events, part 2 (REPLACE-2)

Cardiology Yeung, John Clinical Trial 27,927 Medtronic (USA) Marquis(TM) Dual Chamber Implantable Cardioverter Defibrillator Clinical StudyCardiology Yeung, John Clinical Trial 3,276 Medtronic of Canada Ltd. InSync ICD: Clinical study evaluating cardiac resynchronization therapy for heart failure patients

with ICD indicationsCritical Care Chittock, Dean Grant 1,840 National Institutes of Health FACTT: Prospective Randomized Multicenter Trial of Pulmonary Artery Catheter (PAC) vs Central

Venous Catheter (CVC) for Management of Acute Lung Injury (ALI) & Acute Respiratory Distress Syndrome (ARDS)

Critical Care Chittock, Dean Grant 7,600 Society of Critical Care Medicine Effect of Measuring Sedation and Agitation on Duration of Mechanical Ventilation

Critical Care Chittock, Dean Grant 34,345 VHHSC: VGH/UBC Fdn Special Opportunities Research Fund

The Vancouver Interaction and Calmness Scale in Mechanically Ventilated Patients: A Prospective Randomized Controlled Trial of the Effect of Measuring Sedation and Agitation on the Duration of Mechanical Ventilation

Critical Care Chittock, Dean Grant 50,000 Society of Critical Care Medicine Does using a scale to measure the quality of sedation in the critically ill reduce the duration of mechanical ventilation: randomized controlled trial

Critical Care Dodek, Peter Grant 12,500 St. Paul's Hospital Satisfaction with care in the Intensive Care Unit: as assessment of the family's perspective

Critical Care Dodek, Peter Grant 6,450 Queen's University A randomized trial of empiric broad-spectrum antibiotics and invasive diagnostic techniques in the setting of ventilator-associated pneumonia

Critical Care Dodek, Peter Grant 20,000 BC Medical Services Foundation Determinants of outcomes for critically ill patients who are transported between hospitals

Critical Care Dorscheid, Delbert Grant 63,874 Parker B. Francis Fellowship in Pulmonary Research

Corticosteroid-induced airway epithelial cell apoptosis





Critical Care Dorscheid, Delbert Grant 61,053 Parker B. Francis Fellowship in Pulmonary Research

Corticosteroid-induced airway epithelial cell apoptosis

Critical Care Dorscheid, Delbert Agreement 28,000 National Heart, Lung and Blood Institute R01 HL63300, 5-20292

Mechanisms of airway epithelium apoptosis

Critical Care Dorscheid, Delbert Grant 22,500 BC Lung: Project Grant Airway Permiability in Chronic Corticosteroid Administration to HumansCritical Care Dorscheid, Delbert Grant 84,536 H&SFBC: Research Endothelial FasL Expression and Reperfusion InjuryCritical Care Dorscheid, Delbert Grant 80,069 CIHR: Operating Grant # MOP-

43898Airway epithelial injury as a result of corticosteroid-induced apoptosis

Critical Care Dorscheid, Delbert Clinical Trial 45,000 Natural ASA The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma and AllergyCritical Care Dorscheid, Delbert Grant 98,806 NIH (US): Research Grant Eosinophil-Airway Epithelial Fas-Fasl InteractionsCritical Care Fenwick, John Contract 113,377 Eli Lilly Canada Inc. UBC: A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute

Lung Injury.Critical Care Fenwick, John Clinical Trial 53,106 Eli Lilly Canada Inc. Protocol H6W-MC-MCAA. A study to determine the efficacy and safety of Sivelestat in acute lung

injury.Critical Care Fenwick, John Clinical Trial 148,687 Eli Lilly and Company, US A randomized trial of a Lung Open Ventilation Strategy in Acute Lung Injury (MRC #78042)Critical Care Ronco, Juan Clinical Trial 5,525 Medical Research Council A randomized trial of a Lung Open Ventilation Strategy in Acute Lung Injury (MRC #78042)Critical Care Ronco, Juan Clinical Trial 13,605 AstraZeneca Canada Inc A Multicentre, Randomized, Comparative Study of Intravenous Merrem (Meropenem) vs Primaxin

(Imipenem-Cilastatin in the Treatment of Subjects with Hospital-Acquired Pneumonia

Critical Care Russell, James Agreement 82,353 NIH (US): Research Grant N01-HR-16148

Clinical Centers for the Clinical Network for the Treatment of the Adult Respiratory Distress Syndrome

Critical Care Russell, James Grant 553,954 CIHR: Clinical Trials MCT-44152 Randomized controlled trial of vasopressin vs. norepinephrine in septic shock

Critical Care Russell, James Contract 4,250 Medical Research Council A randomized trial of a lung open ventilation strategy in acute lung injuryCritical Care Russell, James Clinical Trial 41,688 Eli Lilly and Company, US An open-label study of recombinant human activated protein C in severe sepsis: A phase 3b

clinical trial (Protocol F1K-MC-EVBF)Critical Care Russell, James Clinical Trial 10,546 Eli Lilly and Company, US Phase 2 Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung

InjuryCritical Care Russell, James Clinical Trial 10,634 Eli Lilly and Company, US Long Term Follow-Up of Survivors From the PROWESS Trial (An Observational Study)

Critical Care Russell, James Clinical Trial 1,200 Eli Lilly Canada Inc. A phase three study to determine the efficacy and safety for recombinant human activated protein C in severe sepsis

Critical Care Russell, James Clinical Trial 34,747 St. Paul's Hospital Albumin ameliorates the inflammatory response to and organ dysfunction after cardiac surgery especially in patients with TNF, IL1 RA and IL6 polymorphisms

Critical Care Russell, James Clinical Trial 11,368 ICOS Corporation A phase 3 study to demonstrate the safety and efficacy of recombinant platelet-activating factor acetylthydrolase (rPAF-AH, Pafase(R)) for reducing 28 day all cause mortality in patients with severe sepsis

Critical Care Walley, Keith Grant 20,000 VPR Research Development Fund

Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post-cardiopulmonary bypass surgery

Critical Care Walley, Keith Grant 98,948 H&SFBC: Research Mechanism of Myocardial Dysfunction during Sepsis





Critical Care Walley, Keith Grant 119,197 CIHR: Operating Grant MOP-53051

Myocardial Dysfunction Induced by ICAM-1 binding.

Critical Care Walley, Keith Grant 48,766 CIHR: Operating Grant MOP 57774

Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post-cardiopulmonary bypass surgery

Critical Care Walley, Keith Grant 65,000 BC Lung Association BC Lung/St. Paul's Hospital Scientist Award: Cytokine signalling in acute respiratory distress syndrome

Dermatology Dutz, Jan Grant 50,000 Arthritis Society: Research TAS01/0116

UV Light, Apoptosis and T Cell Priming in the Skin

Dermatology Dutz, Jan Grant 100,884 MRC Operating Grant MOP37952

Epicutaneous priming of T lymphocytes

Dermatology Dutz, Jan Grant 45,000 Arthritis Soc/CIHR: New Investigator Award TAS00/0143

Transcutaneous T cell priming

Dermatology Dutz, Jan Grant 20,000 VPR Research Development Fund

Treating type I diabetes melitus by modulating cross-presentation

Dermatology Dutz, Jan Grant 67,800 BCRICWH: Investigatorship BCRICWH: Investigatorship Award: Jan DutzDermatology Dutz, Jan Contract 25,000 Galderma Canada Clinical-Experimental DermatologyDermatology Dutz, Jan Grant 68,799 Canadian Diabetes Assoc Autoreactive CTL in DiabetesDermatology Dutz, Jan

(Co-investigator)Grant 94,935 NCIC Lymphocyte defects in X-linked lymphoproliferative disease

Dermatology Dutz, Jan (Co-investigator)

Grant 3,138,450 Canadian Foundation for Innovation

Center for Childhood Diabetes Research

Dermatology Ho, Vincent Clinical Trial 356 Fujisawa Canada Inc. An open-label, long-term follow-up study to Evaluate the safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis in pediatric patients

Dermatology Ho, Vincent Clinical Trial 3,292 Fujisawa Canada Inc. An open-label study to evaluate the safety of topically applied tacrolimus ointment for the treatment of atopic dermatitis

Dermatology Ho, Vincent Clinical Trial 22,885 Leo Laboratories Canada Ltd Cipamfylline Ointment in Atopic Dermatitis

Dermatology Ho, Vincent Clinical Trial 3,000 Novartis Pharmaceuticals Canada Inc

CASM981CJP01(ASM981C): Open-Label Multicenter Study to Assess Blood Concentrations Tolerability & Efficacy of ASM981 in Japanese Infants & Children with Atopic Dermatitis Treated Topically for 3 Weeks with 1% ASM981 Final Market Formulation


RAINBOW: A Multicenter, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic Dermatitis


A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Finding Study to Determine the Dose-Response, Safety and Tlerability of Three Doses (10,20,30 mg bid) of SDZ ASM 981 Tablets in Subjects with Chron..

Dermatology Kitson, Neil Clinical Trial 2,560 Novartis Pharmaceuticals Canada Inc


Dermatology Li, Gang Grant 19,530 VHHSC Fellowship James A. Winton Endowment Fund - Mechanisms of Curcumin-Induced Apoptosis in Human Melanoma Cells.





Dermatology Li, Gang Grant 1,500 NCIC/CCS: Student Travel Award 013433

Jason Bush: 93rd Annual American Associate for Cancer Research, San Francisco, CA "Tissue-specific regulation of the murine ABCB1 homologue by p53"

Dermatology Li, Gang Grant 20,000 VPR Research Development Fund

Skin Cancer prevention by pharmacological stabilization of p53 conformation.

Dermatology Li, Gang Grant 44,582 CIHR: Operating Grant MOP-42465

Role of p33ING1 in repair of UV-damaged DNA

Dermatology Li, Gang Grant 85,882 NCIC/CCS: Research Scientist 012443

Role of p33ING1 in repair of UV-damaged DNA

Dermatology Li, Gang Grant 3,125 CIHR: Operating Grant DOP 62280

Mechanisms of the novel tumour suppressor p331NG1 in UV-induced apoptosis of melanoma cells

Dermatology Lui, Harvey Clinical Trial 3,520 Novartis Pharmaceuticals Canada Inc

Rainbow Study: A Multicentre, Single Arm Prospective, Open Label Study to Assess the Safety of Elidel (SDZ ASM 981 - Pimecrolimus) Cream 1% in Patients with Atopic dermatitis.

Dermatology Lui, Harvey Clinical Trial 36,534 Galderma Canada Protocol RD.06.SPR18091: An Open Label Safety and Efficacy Study of Solage (2% 4-Hydroxyanisole/0.02% Tretinoin) to Assess Pigmentary Changes in Ethnic Groups of Asian, Latin/Hispanic and African American Descent with Skin types II-V

Dermatology Lui, Harvey (Co-Investigator)

Grant 47,097 NCIC Rapid Raman spectroscopy for noninvasive diagnosis: application in skin cancer detection

Dermatology Lui, Harvey Grant 4,780 Canadian Institute of Health Research STM 60424

Development Grant: CIHR Skin Research Training Centre

Dermatology Prendiville, Julie Contract 6,309 Novartis Pharmaceuticals Canada Inc

A multicentre, single arm prospective, open label study to assess the safety of Elidel R (SDZ ASM 981-pimecrolimus) cream 1% in patients with atopic dermatitis (Rainbow Study)

Dermatology Rivers, Jason Clinical Trial 17,042 Allergan Inc 190168-049 P: Multi-Centre Double-Blind Randomized Placebo-Controlled Study of the Safety and Efficacy of 12 Wk Treatment with Tazarotene 4.5 mg Capsules Once Daily Followed by a 12 Wk Post-Treatment F/U Period in Pts with Moderate to Very…

Dermatology Rivers, Jason Clinical Trial 30,595 Allergan Inc F/U Study: Multicenter Open Label Safety Study of Tazarotene 4.5 mg Capsules Administered Once Daily for 12 Weeks Followed by a 12 Week Post-Treatment F/U Period in Patients with Plaque Psoriasis Who Have No Change or an Increase in Their…

Dermatology Rivers, Jason Clinical Trial 2,560 Novartis Pharmaceuticals Canada Inc


Dermatology Shapiro, Jerry Grant 10,000 Cdn Dermatology Fdn: Research Grant

Melanogenesis Regulation of Graying Human Hair Follicles.

Dermatology Shapiro, Jerry Grant 73,392 Canadian Hair Research Foundation

Canadian Hair Research Foundation

Dermatology Shapiro, Jerry Clinical Trial 2,370 Novartis Pharmaceuticals Canada Inc


Dermatology Shapiro, Jerry Grant 2,298 Natl Alopecia Areata Fdn: Research Grant

Gene expression profiling mediated by anthralin in alopecia areata-affected debr rats

Dermatology Zhou, Youwen Grant 50,000 Canadian Dermatology Foundation

Molecular pathogenesis of Sezary Syndrome - gene signatures of sezary cells

Dermatology Zhou, Youwen Grant 20,000 VPR Research Development Fund

T-plastin in cutaneous T cell lymphoma: pathogenic significance and diagnostic value





Dermatology Zhou, Youwen Grant 75,000 Medicine Research Coordinating Committee

Faculty start-up: Acquired genetic alterations in cutaneous T cell Lymphomas.

Dermatology Zhou, Youwen Grant 20,000 VPR Research Development Fund

Genomic signatures of drug hypersensitivity syndrome (DHS)

Dermatology Zhou, Youwen Grant 30,000 VHHSC Scholar Award Molecular Pathogenesis of Sezary Syndrome - Gene Signatures of Sezary CellsDermatology Zhou, Youwen Contract 25,000 Galderma Canada Clinical-Experimental DermatologyDermatology Zhou, Youwen Grant 50,000 Canadian Dermatology

FoundationMolecular Phatogenesis of Sezary Syndrome

Dermatology Zhou, Youwen Clinical Trial 2,560 Novartis Pharmaceuticals Canada Inc


Endocrinology Dawson, Keith Grant 2,400 Medical Research Council CANENDIT: Screening and prevention of insulin dependent diabetes mellitus (IDDM)Endocrinology Dawson, Keith Clinical Trial 1,830 Hoechst-Roussel

Pharmaceuticals, USHOPE Study: Heart Outcomes Prevention Evaluation

Endocrinology Elliott, Tom Clinical Trial 74,131 National Institutes of Health Action to control Cardiovascular Risks in Diabetes (ACCORD) TrialEndocrinology Elliott, Tom Clinical Trial 22,556 Novartis Pharmaceuticals

Canada IncNAVIGATOR: Multinational Randomized Double-Blind Placebo-Controlled Forced-Titration 2x2 Factorial Design Study of the Efficacy & Safety of Long Term Administration of Nateglinide & Valsartan in the Prevention of Diabetes & Cardiovascular..

Endocrinology Elliott, Tom Clinical Trial 9,180 Laboratoires Fournier S.C.A. Diabetes atherosclerosis intervention study (DAIS)Endocrinology Prior, Jerilyn Clinical Trial 31,127 Eli Lilly Canada Inc. H3S-CA-

O0006Raloxifene, Vasomotor symptoms and Endothelial function Protocol # H3S-CA-O0006

Endocrinology Prior, Jerilyn Grant 45,953 Cancer Care Ontario (CAMOS) Canadian multicentre osteoporosis study - a cross sectional and prospective observational study of bone density, bone strength and fracture risk.

Endocrinology Prior, Jerilyn Grant 29,203 Donations for Health Science Research

Exercise, Reproduction and Health Research Fund

Endocrinology Prior, Jerilyn Grant 61,545 MRC/PMAC: Health Program (CAMOS) - a cross sectional and prospective observational study of bone density, bone strength and fracture risk

Endocrinology Prior, Jerilyn Grant 40,878 Vancouver Hospital and Health Science Centre

Centre for menstrual cycle and ovulation research

Endocrinology Prior, Jerilyn Contract 3,000 Schering Canada Inc. Centre for menstrual cycle and ovulation researchEndocrinology Sadar, Marianne Grant 1,459 MSFHR: Doctoral Trainee

Research Award 75(02-1)BM Identification of new targets for the treatment of androgen-independent prostate cancer

Endocrinology Sadar, Marianne Grant 500 CIHR: Doctoral Research Awards JMO 58977

Identification of new targets for the treatment of androgen-independent prostate cancer

Endocrinology Sadar, Marianne Grant 102,000 Health Canada Androgen independenceEndocrinology Sadar, Marianne Grant 100,000 Health Canada Potential new therapy for androgen independentEndocrinology Thompson, David Grant 108,667 CIHR: Health Research Institutes Trial to reduce IDDM in type 1 diabetes in the genetically at risk TRIGR

Gastroenterology Amar, Jack Clinical Trial 22,911 Novartis Pharmaceuticals Canada Inc

A randomized, double blind, placebo-controlled multicenter study to assess the efficacy, safety and tolerability of tegaserod 2mg bid and 6mg bid given orally vs placebo in patients with chronic constipation





Gastroenterology Anderson, Frank Clinical Trial 6,000 Hoffmann-La Roche Ltd (Canada) BV16209E. Multicenter open label expended access program of Peginterferon alfa-2a (Ro25-8310) Monotherapy and Combination Therapy with Rivavirin (Ro 20-9963) in patients with Chronic Hepatitis C

Gastroenterology Anderson, Frank Clinical Trial 12,619 Hoffmann-La Roche Ltd (Canada) Phase 3 Partially Double-Blind Study Evaluating the Efficacy and Safety of 40kD Branched Pegylated Interferon Alfa 2a (PEG-IFN Ro 258310) Combined with Placebo or Lamivudine in Anti Hbe Positive Patients with Chronic Hepatitis B

Gastroenterology Anderson, Frank Clinical Trial 2,062 Centocor A randomized double blind, placebo controlled trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, remicade) in the long term treatment of patients with fistulizing Crohn's Disease (BBD-IND 5389) Accent II

Gastroenterology Anderson, Frank Clinical Trial 315 Centocor A randomized double blind, placebo-controlled trial of anti-TNfx chimeric monoclonal antibody (Infliximab, remicade) in the long term treatment of patients with moderately to severely active Crohn's Disease ACCENT I

Gastroenterology Anderson, Frank Clinical Trial 16,194 ISIS Pharmaceuticals (ISIS 2302-CS20): Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302) an Antisense Inhibitor of ICAM-1, for the Treatment of Patients with Active Crohn's Disease.

Gastroenterology Anderson, Frank Clinical Trial 10,500 Bristol-Myers Squibb Company (Cda)

A Phase II study of the safety and efficacy of oral BMS-200475 in adults with chronic hepatitis "B" - Protocol AI463-005

Gastroenterology Anderson, Frank Clinical Trial 20,455 Celltech Chiroscience Inc. 36week -A Phase 3 Multi-national multi-site, double-blind, placebo-controlled, parallel Group 36 week study to assess the efficacy and safety of the engineered human anti TNFa antibody CDP571, to prevent disease flare whilst ..(013)

Gastroenterology Anderson, Frank Clinical Trial 27,687 Elan Pharmaceuticals Inc. A Phase III, International Multicentre, Double-Blind, Placebo Controlled Study of the Safety, Efficacy and Tolerability of Intravenous Antegren (Natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease.

Gastroenterology Anderson, Frank Clinical Trial 16,660 Bristol-Myers Squibb Pharmaceutical Group (Cda)

A Phase 3 Study of the Comparison of Entecavir to Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current Lamivudine Therapy


A1463-027 A Phase II Study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hapatitis B infection who are negative for hepatitis B E Antigen


APhase III study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hepatitis B infection who are posititve for hepatitis B E antigen BMS AI463-022

Gastroenterology Anderson, Frank Clinical Trial 17,751 Millenium Pharmaceuticals Inc. Phase II randomized, placebo controlled, double blind, parallel group, multicentre study to determine the safety, pharmacokinetics and effectiveness of LDP-02 in patients with mildly to moderately active Ulcerative colitis

Gastroenterology Anderson, Frank Clinical Trial 21,286 Celltech Chiroscience Inc. A Phase II, multi-centre, double-blind, placebo-controlled, parallel group, dose response study to assess the safety and efficacy of the humanised anti-TNF PEG conjugate, CDP870, dosed subcutaneously in patients with active Crohn's disease

Gastroenterology Anderson, Frank Clinical Trial 7,291 Celltech Chiroscience Inc. (32 week).A Phase III, multi-national, multi-site, open label 32 week long term follow-up study to assess the safety and efficacy of the engineered human anti-TNFa antibody, CDP571, in patients with Crohn's Disease. (014)

Gastroenterology Enns, Robert Grant 30,000 Canadian Society of Intestinal Research

Colon Cancer Screening: What are we doing? Is it cost-saving?

Gastroenterology Enns, Robert Clinical Trial 14,715 Searle Canada Ltd A randomized, double-blind, placebo-controlled study of the efficacy and safety of Celecoxib (SC-58635) in the prevention of colorectal sporadic adenomatous polyps (EQ4-00-02-018)





Gastroenterology Enns, Robert Grant 25,182 Various Sources General GI ResearchGastroenterology Enns, Robert Clinical Trial 354,351 Elan Pharmaceuticals Inc. A phase III, international, multicenter, double-blind, placebo-controlled study of the safety, efficacy

and tolerability of intravenous Antegren (TM) (natalizumab) in subjects with moderately to severely active Crohn's disease

Gastroenterology Enns, Robert Clinical Trial 25,900 GlaxoSmithKline An eight-week, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety of SB223412 in subjects with irritable bowel syndrome

Gastroenterology Enns, Robert Clinical Trial 105,493 Celltech Chiroscience Inc. A phase III, multi-national, multi-site, double-blind, placebo-controlled, 28-week study to assess the safety and efficacy of the engineered human anti-TNF alpha antibody, CDP571 (10mg/kg), in patients with active Crohn's disease

Gastroenterology Enns, Robert Clinical Trial 29,805 Byk Gulden Pharmaceuticals Initial study for the development and validation of a comprehensive questionnaire assessing disease-related symptoms in patients suffering from endoscopic negative gastroesophageal reflux disease and treated with Pantoprazole 20mg over 28 d

Gastroenterology Enns, Robert Clinical Trial 1,000 Wyeth-Ayerst Research A randomized, double-masked, placebo-controlled study of subcutaneously administered recombinant human interleukin-11 (rhIL-11) in patients with active Crohn's disease on or off concomitant systemic corticosteroid treatment

Gastroenterology Enns, Robert Clinical Trial 4,800 Solvay Pharmaceuticals A randomized, double blind, placebo controlled, multinational study to investigate the safey and efficacy of 2mg TID of Cilansetron over 26 weeks in Diarrhea-Predominant Irritable Bowel Syndrome subjects (Protocol S2413009)

Gastroenterology Enns, Robert Grant 2,700 Various SourcesGastroenterology Gray, James Clinical Trial 10,500 Altana Pharma Inc Protocol BY1023/M3-317: EASYGERD - Evaluation of Symptoms of GERDGastroenterology Gray, James Clinical Trial 1,250 GlaxoSmithKline Protocol 223412/067: An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-

Ranging Study to Evaluate Efficacy and Safety of SB 223412 in Subjects with Irritable Bowel Syndrome

Gastroenterology Salh, Baljinder Grant 40,000 NSIR: Research Grant The role of integrin - linked kinase in intestinal inflammationGastroenterology Salh, Baljinder Grant 2,500 MSFHR: Masters Trainee

Research Award # 30(02-1)BMThe Role of the Integrin Linked Kinase in Intestinal Inflammation

Gastroenterology Salh, Baljinder Grant 75,000 CCFC: Research Signalling and Inflammatory Bowel Disease: the Role of Stress-Activated Protein KinasesGastroenterology Steinbrecher, Urs Grant 55,000 Geraldine Dow Ferry Endowment

FundEndowment for inflammatory bowel disease research and education

Gastroenterology Steinbrecher, Urs Grant 114,906 H & SFBC: Research Regulation of Macrophage Growth and Survival by Oxidized LDL.Gastroenterology Steinbrecher, Urs Grant 1,070 Donation Clinical Research in Chronic Liver DiseasesGastroenterology Steinbrecher, Urs Grant 64,380 MRC: Operating Grant MOP

8630Pathogenesis of atherosclerosis

Gastroenterology Whittaker, Scott Clinical Trial 23,557 Millennium Pharmaceuticals A phase II, randomized, placebo-controlled, double-blind, parallel group to determine the safety, pharmacokinetics and effectiveness of LPD-02 in patients with mildly to moderately active Crohn's DiGastroenterology Whittaker, Scott Clinical Trial 7,422 Millennium Pharmaceuticals A phase II, randomized, placebo-controlled, double-blind, parallel group, multicenter study to determine the safety, pharmacokinetics and effectiveness of LDP-02 in patients with mildly to moderately active ulcerative colitis

Gastroenterology Whittaker, Scott Clinical Trial 59,820 Celltech Chiroscience Inc. A phase II, multi-centre, double-blind, placebo-controlled, parallel group, dose response study to assess the safety and efficacy of the humanised anti-TNF PEG conjugate, CDP870, dosed subcutaneously in patients with active Crohn's disease





Gastroenterology Yoshida, Eric Clinical Trial 7,500 Hoffmann-La Roche Ltd (Canada) BV16209 A multicenter open label expanded access program of Pegintereron alfa-2a (ro 25-8310) Monotherapy and combination Therapy with Ribavirin (Ro20-9963) in patients with Chronic Hepatitis C

General Internal Med. Magee, Laura Grant 50,000 BCRICWH: Investigator Establishment Award

BCRICWH: Establishment Award

General Internal Med. Magee, Laura Clinical Trial 523 Roberts Pharmaceuticals Magee WorkshopGeneral Internal Med. Montaner, Julio Grant 22,750 MSFHR: Postdoctoral Trainee

Fellowship 240(02-1)POPAdverse drug effects among persons using antiretroviral therapy for HIV disease and impact on treatment patterns

General Internal Med. Montaner, Julio Clinical Trial 166,392 Abbott Laboratories A pilot study of a nucleoside analogue reverse transcriptase inhibitor sparing regimen in antiretroviral-naive, HIV-infected patients

General Internal Med. Montaner, Julio Clinical Trial 41,128 Hoffmann-La Roche Ltd (Canada) A phase III open-label, randomized, active-controlled study assessing the efficacy and safety of T-20/Ro 29/9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in patients

General Internal Med. Montaner, Julio Clinical Trial 52,982 Hoffmann-La Roche Ltd (Canada) A randomized, open-label, multicenter, phase III, three arm study evaluating the efficacy and safety of Pegylated-interferon a-2a(Ro25-8310) monotherapy versus combination therapy of interferon a-2a(Ro22-8181) with Ribavirin for 48 weeks

General Internal Med. Montaner, Julio Clinical Trial 2,185 Chiron Corporation A phase III multicenter randomized study of the biological and clinical efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT)

General Internal Med. Montaner, Julio Clinical Trial 4,267 GlaxoSmithKline A phase III, open-label, comparative, multicentre trial to test the concept of durable virological suppression in subjects with primary HIV-1 infection or recent seroconversion after an intensive induction regimen of quadruple HAART (ZDV/3T

General Internal Med. Montaner, Julio Clinical Trial 53,500 GlaxoSmithKline Randomized, open label study of continued stavudine vs abacavir substitution with or without riboflavin and thiamine supplementation in HIV-infected patients who have elevated venous lactic acid while on stavudine-based therapy

General Internal Med. Montaner, Julio Clinical Trial 1,000 Various Pharmaceutical Companies

The Canadian Women's HIV Study - A study of the relationship between human papilloma virus infection, human immunodeficiency virus infection and cervical disease using cross-sectional, cohort and descriptive methodologies

General Internal Med. Montaner, Julio Contract 227,074 Boeringher Ingelheim (Canada) Ltd

A pilot protocol to evaluate the effect of Nevirapine on biochemical markers of cardiovascular risk in HIV-infected individuals receiving a protease inhibitor based regimen

General Internal Med. Montaner, Julio Clinical Trial 11,800 Bristol-Myers Squibb Company (Cda)

A study to compare long-term safety and tolerability of Stavudine (d4T) extended release (ER) versus conventional (immediate release, IR) formulations, each in combination with Lamivudine (3TC) and Efavirenz (EFV) in subjects who have…

General Internal Med. Montaner, Julio Clinical Trial 2,416 Bristol-Myers Squibb Pharmaceutical Group (Cda)

The safety and antiviral efficacy of Stavudine extended release formulation as compared to Stavudine immediate release formulation, each as part of potent antiretroviral combination therapy (P t l AI455 099)General Internal Med. Montaner, Julio Clinical Trial 27,283 CIHR/Rx&D: Research Program -

Clinical TrialAn open label, randomized study to evaluate the antiretroviral effect, tolerability, safety and pharmacokinetics of squinavir SGC/Ritonavir QD vs. indinavir/norvir BID in HIV infected patients

General Internal Med. Montaner, Julio Grant 32,900 CIHR/Rx&D: Research Program - Clinical Trial

Randomized, open-label study of continued stavudine vs. abcavir substitution with or without riboflavin and thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy





General Internal Med. Montaner, Julio Clinical Trial 2,300 Merck Frosst Canada & Co. A probe study to evaluate HIV-1 specific cell mediated immune responses in HIV-1 infected patients treated with potent antiretroviral therapy (ART) during acute or recent infection (PR013-00)

General Internal Med. Montaner, Julio Clinical Trial 42,800 GlaxoSmithKline A pilot study of mycophenolate among patients with human immunodeficiency virus (HIV) disease receiving Abacavir-containing antiretroviral therapy regimens

General Internal Med. Montaner, Julio Clinical Trial 3,745 GlaxoSmithKline A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who Developed Hypersensitivity Following Treatment with Abacavir (Protocol CNA30032)

General Internal Med. Montaner, Julio Clinical Trial 27,283 CIHR/Rx&D: Research Program - Clinical TrialsDCT-48206

An Open Label, Randomized Study to Evaluate the Antiretroviral Effect, Tolerability, Safety and Pharmacokinetics of Squinavir SGC/Ritonavir QD vs. Indinavir/Norvir BID in HIV Infected Patients.

General Internal Med. Montaner, Julio Grant 32,900 CIHR/Rx&D: Research Program - Clinical TrialsDCT-51595

Randomized, open-label study of continued stavudine vs. abcavir substitution with or without riboflavin and thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy.

General Internal Med. Ong-Lam, May Clinical Trial 49,000 Janssen-Ortho Inc. A study of Duragesic* (TTS Fentanyl) compared to sustained release Morphine (MS Contin) in subjects with chronic non-cancer pain

General Internal Med. Palepu, Anita Grant 2,000 CIHR: New Investigator Award (CIHR Scholarship)

Social determinants and HIV: an evaluation of a community-based intervention in injection drug users (research allowance)

General Internal Med. Palepu, Anita Grant 46,581 CIHR: Operating Grant # MOP-53058

Development and Preliminary Validation of a Quality of Life Instrument for Injection Drug Users.

General Internal Med. Palepu, Anita (Co-investigator)

Grant 36,446 CIHR: Operating Grant Feasibility study for a safe injection facility in the downtown eastside of Vancouver

General Internal Med. Palepu, Anita Grant 39,626 CIHR: Operating Grant The role of injection drug use and hepatitis C infection on tolerability of highly active antiretroviral therapy and HIV-1 treatment outcomes


Grant 100,000 CIHR: Network Grant Research Alliance for Canadian Homelessness, Housing and Health


Grant 49,700 BC Medical Services Foundation Contraceptive decisions of Canadian HIV-positive women

General Internal Med. Palepu, Anita Grant 48,000 CIHR: New Investigator Award (CIHR Scholarship) # HNI-50103

Social determinants and HIV: a community-based intervention in injection drug users (IDUs)

General Internal Med. Studney, Donald Clinical Trial 59,663 Aventis Pharma Inc. # HMR1964A/3004

12 Week, Multinational, Multicentre, Controlled, Open 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiority Between Pre and Post-Meal Administration of HMR 1964 and Pre-Meal Regular Insulin in Type 1 Diabetis Mellitus Receiving

General Internal Med. Studney, Donald Clinical Trial 4,875 Aventis Pharma Inc HOE 901/3502: Open-Label, Multicentre, Randomized Study to Assess an Early Insulization Strategy with Insulin Glargine vs a Standard Oral Strategy in the Management of Type 2 Diabetes.

Geriatric Medicine Adler, Reva Grant 12,956 Vancouver Foundation DOM LTC Study: Outcomes in Long-Term Care: Does Type of Ownership Matter?Geriatric Medicine Beattie, Lynn Grant 58,520 ASC: Research Grant 02-51 CSHA-BC Cohort Linkage: Characterization, predition and costs of health services.Geriatric Medicine Meneilly, Graydon Grant 420,491 UBC Overhead Recovery Research overhead and royaltiesGeriatric Medicine Meneilly, Graydon Clinical Trial 4,106 Servier Canada Protocol IC4-5702-001-CAN: Randomized Double-Blind Active-Controlled Parallel-Group

Multicentre Study of the Efficacy & Safety of Oral Gliclazide Modified Release Compared to Oral Glyburide in Elderly Type 2 Diabetic Patients





Geriatric Medicine Meneilly, Graydon Grant 74,914 Cdn Diabetes Assoc: Charles H. Best Fund/Grant-in-Aid # 993

Diabetes in the Elderly

Geriatric Medicine Meneilly, Graydon Grant 72,000 H&SFBC: Research Effect of aging and diabetes on insulin mediated blood flowGeriatric Medicine Meneilly, Graydon Grant 5,000 CIHR: New Emerging Team Exercise and diabetes in the elderlyHematology Benny, Barrett Grant 1,200 Canadian Institutes of Health

ResearchViral surveillance in apheresis & Comparison of solvent detergent treated plasma (SDP) vs cryosupernatant plasma (CSP) as replacement fluid in the treatment of thrombotic thrombocytopenic purpura

Hematology Eaves, Allen/ Eaves, Connie

Grant 149,298 National Cancer Institute Disease Mechanisms in Chronic Myeloid Leukemia (CML)

Hematology Hogge, Donna Clinical Trial 14,273 Janssen-Ortho Inc. The efficacy and safety of the Farnesyl Transferase Inhibitor (FTI) R115777 in patients with Refractory or Relapsed Acute Myeloid Leukemia (AML): An open label, multlicenter, non-comparative Phase 2 study.

Hematology Hogge, Donna Clinical Trial 11,035 Maxim Pharmaceuticals Inc. Multi-center, randomized open label study to evaluate the safety and efficacy of immunotherapy with subcutaneous maxamine (Histamine dichloride) plus proleukin versus no treatment (standard of care) in patients with acute myeloid leukemia

Hematology Hogge, Donna Grant 97,661 National Cancer Institute Regulation of Primitive Acute Myelogenous Leukemia Progenitors in vitro and in vivoHematology Humphries, Keith Grant 2,500 MSFHR: Doctoral Trainee

Research Award 111-BMThe Role of Homeobox Transcription Factors in Hematopoietic Stem Cell Function.

Hematology Humphries, Keith Grant 132,751 National Cancer Institute Genetic Determinants of Stem Cell FunctionHematology Humphries, Keith/

Kay, RobertGrant 58,668 Medical Research Council Functional Analysis of Hemopoietic Cell Surface Molecules

Hematology Humphries, Keith/ Kay, Robert

Grant 59,818 Medical Research Council Roles of G Protein-coupled Receptors in Hemopoiesis & Leukemogenesis

Hematology Humphries, Keith Grant 1,300 Medical Research Council C Abramovich Postdoctoral FellowshipHematology Humphries, Keith Grant 500 Medical Research Council J Wan StudentshipHematology Humphries, Keith/

Eaves, ConnieGrant 592,870 National Institute of Health Gene Transfer and Stem Cell Biology in Sickle Cell Disease

Hematology Humphries, Keith Grant 84,459 National Institute of Health Role of Homeobox Genes in Early HematopoiesisHematology Lansdorp, Peter Grant 3,775,195 CFI UBCLOI: Institutional

Innovation FundStem Cell Centre

Hematology Lansdorp, Peter Grant 38,500 CIHR: Postdoctoral Fellowship MFE-47697

Role of ataxia telangiectasia (ATM) gene in telomere function

Hematology Lansdorp, Peter Grant 113,500 CIHR: Operating Grant MOP 38075

Replicative Shortening of Telomeres in Human Cells

Hematology Lansdorp, Peter Grant 135,479 National Cancer Institute Self-renewal & Telomere Dynamics in Murine Embryonic and Hematopoietic Stem Cells

Hematology Lansdorp, Peter Grant 235,800 National Institute of Health Activation and Proliferation of Purified Hemopoietic Stem Cells

Hematology Lansdorp, Peter Grant 70,000 Science Council of BC Equipment: Delta Vision Optical Sectioning Microscope





Hematology Lansdorp, Peter Grant 30,612 Highbury Foundation Equipment: Delta Vision Optical Sectioning Microscope

Hematology Lansdorp, Peter Grant 5,000 CIHR: Workshops & Symposia MWS 52288

3rd Canadian Symposium on telomeres and telomerese

Hematology Nevill, Thomas Clinical Trial 5,875 SangsStat Canada Ltd. SMC-101-1020 An open label prospective, Stratified, randomized,controlled, multicenter PhaseIIB study of the impact of thymoglobin therapy on transfusion needs of patients..SMC-101-1022 A Three Year Evaluation of the overall and Leukemic fre.

Hematology Schrader, John Grant 40,000 NCE/Protein Engineering: Research Pence P3 Deg4

Pence P3 Deg4

Hematology Schrader, John Grant 39,000 MSFHR: Doctoral Trainee Research Award 32-BM:S h b t P t

Structure-Function Relationship of the GTP-exchange Factor smgGDS and its Role in Breast Cancer.

Hematology Schrader, John Grant 56,000 NCE/Protein Engineering: Tech 5: Cell Surface MappingHematology Schrader, John Grant 200,000 Canada Research Chair Tier I

(CIHR)Canada Research Chair - John Scrader

Hematology Shepherd, John Clinical Trial 5,119 Novartis Pharmaceuticals Canada Inc

A phase III study of ST1571 versus Interferon-a (IFN-A) combined with Cytarabine (Ara-C0 in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)

Hematology Shepherd, John Clinical Trial 12,710 Novartis Pharmaceuticals Canada Inc

CSTI571,0113,0114,0115 AStudy to Determine the safety and efficacy of STI571 in patients with chronic myeloid leukemia who are Hematologically or Cytogenetically resistant or refractory to interferon-alpha or Intolerant of Interferon-alpha

Hematology Sutherland, Heather Clinical Trial 2,000 Aeterna Laboratories Inc AE-941 (Neovastat) in refractory and early relapse multiple myeloma patients

Hematology Sutherland, Heather Grant 33,230 Leukemia Research Fund

Hematology Vickars, Linda Clinical Trial 5,518 Inex Pharmaceuticals Corp. Pivotal phase II multicenter study of Vincristine Sulfate liposomes injection in aggressive Non-Hodgkin's Lymphoma that is refractory or relapsed after second line combination chemotherapy (Protocol No.: CA99002)

Hematology Vickars, Linda Clinical Trial 1,725 National Cancer Institute of Canada

A comparative study of dexamethasone vs. prednisone (both in combo with melphalan) as induction therapy in untreated symptomatic myeloma with an additional assessment of dexamethasone vs. no additional treatment as maintenance therapy

Hematology Vickars, Linda Clinical Trial 3,061 Bayer Pharmaceuticals An open phase II multi-center trial of BAY 59-8862 in patients with aggressive refractory non-Hodgkin's lymphoma (100389)

Hematology Vickars, Linda Clinical Trial 2,296 Abbott Laboratories, Limited (Canada)

A safety trial using recombinant Urokinase (ABT-120, urokinase alpha) in the treatment of occluded central venous catheters 2001-007

Hematology Vickars, Linda Clinical Trial 19,436 AstraZeneca Canada Inc A randomized, double-blind, comparative study of H376-95 and Enosaparain for the prevention of venous thromboembolism following total hip arthroplasty

Hematology Vickars, Linda Clinical Trial 1,500 Aeterna Laboratories Inc Neovastat (AE-941) in refractory and early relapse multiple myeloma patients





Hematology Vickars, Linda Clinical Trial 13,859 Asahi Kasei America, Inc. A multicentre, open-label, dose response (phase IIa) study of ART-123 (recombinant human soluble thrombomodulin) by subcutaneous injection in the prevention of postoperative venous thrombosis in patients undergoing elective, unilateral total..

Hematology Vickars, Linda Clinical Trial 30,017 Emisphere Technologies Inc. A randomized, double-blind multicenter study comparing the safety and efficacy of two dosing regimens of oral SNAC/heparin with subcutaneous enoxaparin sodium for the prevention of venous thromboembolic events following elective total hip..

Hematology Vickars, Linda Clinical Trial 20,291 GlaxoSmithKline ThromboEMbolism prevention efficacy and safety trial (TEMPEST): A double-blind four-week study to assess the efficacy, safety and tolerability of SB 424323 in the extended prophylaxis of patients following total hip arthroplasty

Hematology Vickars, Linda Clinical Trial 4,933 Recombinant Urokinase (ABT-120, urokinase alpha) in the treatment of occluded central venous catheters, safety and efficacy trial - 2000-042

Infectious Diseases Ayas, Najib Grant 22,400 BC Lung Project Grant The societal consequences of sleep apneaInfectious Diseases Av-Gay, Yossef Contract 146,519 Cytoclonal Pharmaceutics Inc.

(NOW eXegenics Inc.)Production and characterization of two M. tuberculosis MCA proteins in E. coli

Infectious Diseases Av-Gay, Yossef Contract 103,146 eXegenics Inc. Examination of Exegenics Bromo-tyrosine compounds.

Infectious Diseases Av-Gay, Yossef Contract 10,000 Northern Lipids Inc. Support for Lyposome Formulation of Anti Mycobacterial DrugsInfectious Diseases Av-Gay, Yossef Grant 61,000 BC Lung: Research Grant Role of Cholesterol in Tuberculosis InfectionInfectious Diseases Av-Gay, Yossef Grant 1,375 MRC/PMAC: Health Program Protein Phosphorylation in M. tuberculosisInfectious Diseases Av-Gay, Yossef Grant 69,736 CIHR: Operating Grant Molecular Analysis of Mycobacterium Tuberculosis Protein Kinases and PhosphatesInfectious Diseases Av-Gay, Yossef Grant 25,000 BC Lung/CIHR Investigator JBH Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary).Infectious Diseases Av-Gay, Yossef Grant 36,338 Various Sources Career

Development WardBC Lung Career Development Award and TB Vets Salary Support: Dr. Av-Gay

Infectious Diseases Av-Gay, Yossef Grant 29,250 CIHR: New Investigator Award Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary).Infectious Diseases Av-Gay, Yossef Grant 100,000 CIHR: Proof of Principle PPP

62034Screening of a small molecule compound library against a family of Mycobacterium tuberculosis (TB) targets

Infectious Diseases Av-Gay, Yossef Grant 22,000 Vancouver Hospital & Health Sci Ctr - Operating Funds

Role of cholesterol in tuberculosis infection

Infectious Diseases Av-Gay, Yossef Grant 10,000 VHHD: Scientist Award Salary Support: Dr. Av-GayInfectious Diseases Av-Gay, Yossef Contract 150,896 Cytoclonal Pharmaceutics

Inc.(NOW eXegenics Inc)Production and characterization of two M. tuberculosis MCA proteins in E. coli

Infectious Diseases Brunham, Robert Contract 43,869 Aventis Pasteur Limited Genetics and Immunology of a Virulence-Associated Bacteriophage (Ocpn1) of Chlaymidia pneumoniae

Infectious Diseases Brunham, Robert Grant 121,470 CIHR Immunobiology of C. trachomatis infectionInfectious Diseases Brunham, Robert Grant 46,500 CIHR DNA Vaccine c. trachomatisInfectious Diseases Brunham, Robert Contract 150,000 Aventis Pasteur DNA Vaccine c. trachomatisInfectious Diseases Brunham, Robert Grant 119,088 MRC Group Grant Immunology of c. trachomatis Project 2Infectious Diseases Brunham, Robert Grant 25,000 PMC Labs Chlamydia DNA vaccine developmentInfectious Diseases Brunham, Robert Grant 8,333 MRC Industry/Connaught DNA vaccine for ChlamydiaInfectious Diseases Brunham, Robert Grant 252,560 NIH/U Washington Chlamydia & Gonococcal infection





Infectious Diseases Chow, Anthony Grant 98,020 NCE/Canadian Bacterial: Research

Phase III: D4: Diagnosis of Intracellular Pathogens in Community-Acquired Pneumonia HSP60 Gene Sequences

Infectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship MD/PhD Studentship: Lee, C.H.Infectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship Protective immunity in toxic shock syndromeInfectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship Phagosome biogenesisInfectious Diseases Chow, Anthony Grant 500 MRC: Doctoral Research Awards

ProgramGenetic regulation of Vancomycin resistance in Staphylococcus Haemolyticus

Infectious Diseases Chow, Anthony Grant 500 CIHR: Doctoral Research Awards Induction of T regulatory cells by superantigens.

Infectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship Cytokine-mediated signal transduction in leukemiaInfectious Diseases Chow, Anthony Grant 500 CIHR: Doctoral Research Awards

MDR-46129Function of gamma/delta T cells in modulating the immune response in the pathogenesis of superantigen-secreting S. aureus

Infectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship Chromosomal abnormalities in reproduction failure and developmentInfectious Diseases Chow, Anthony Grant 500 MRC: MD/PhD Studentship MMP-

38300Neuronal pH: Regulation in health and disease

Infectious Diseases Chow, Anthony Grant 500 CIHR: MD/PhD Studentship MMP-48141

The regulation of transcription factors by integrin kinase in cancer cells

Infectious Diseases Chow, Anthony Grant 500 CIHR: MD/PhD Studentship MMP-51735

Chlamydia Trachomatis Genomic Analysis using Fosmid Fingerprinting to Investigate the Genetic Basis of Pathogenicity.

Infectious Diseases Chow, Anthony Grant 500 CIHR: MD/Phd Program Studentship MMP-58293

Identification and validation of genes modulating LDL cholesterol in humans

Infectious Diseases Chow, Anthony Grant 500 CIHR: MD/PhD Program Studentship MMP-58313

The pathogenics of salmonella infection

Infectious Diseases Chow, Anthony Grant 87,839 CBS/CIHR: Partnership in Transfusion Science

Detection of bacterial contamination in platelet concentrates by nucleic acid amplification of hsp60 - a pilot study.

Infectious Diseases Chow, Anthony Grant 5,000 CIHR: Strategic Training Initiatives in Health Research STI-60419

Development grant: UBC training program for translational research in infectious diseases

Infectious Diseases Chow, Anthony Grant 98,278 CIHR: Operating Grant MT-7630 Pathogenesis of Staphylococcal Toxic Shock Syndrome

Infectious Diseases Grigg, Michael Grant 30,000 VHHSC Scholar Award Molecular Basis of Toxoplasma Pathogenesis,Infectious Diseases Grigg, Michael Grant 80,000 MSFHR: Career Investigator

Program (C1-SCH-20(01-2) Molecular basis of Toxoplasma Pathogenesis

Infectious Diseases Harrigan, Paul Grant 20,750 CIHR/Rx&D Research Program - Postdoctoral Fellowship DFE-43158

Development and application of validated methodology utilising tandem mass spectrometry for the quantification of plasma antiretroviral drugs from patients with HIV and/or Hepatitis B or C

Infectious Diseases Harrigan, Paul Richard Grant 19,250 CIHR/Rx&D Research Prgm-Postdoc Fell

Development and application of validated methodology utilising tandem

Infectious Diseases Hmama, Zakaria Grant 37,500 MSFHR: Career Investigator Program C1-SCH-26(01-2)

Establishment grant: Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors





Infectious Diseases Hmama, Zakaria Grant 10,417 MSFHR: Establishment Grant CI-SCH-26(01-2)

Matching Establishment Grant: Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors

Infectious Diseases Hmama, Zakaria Grant 76,827 CIHR: Operating Grant MOP-43891

Cell signaling regulating mycobacterial-macrophage interactions

Infectious Diseases Hmama, Zakaria Grant 70,000 Various Sources: Salary support for Dr. Zakaria Hmama

Salary support: Dr. Hmama: Mechanisms of inhibition of MHC class II trafficking in macrophage infected with Mycobacterium tuberculosis

Infectious Diseases Hmama, Zakaria Grant 30,000 MSFHR: Career Investigator Program C1-SCH-26(01-2)

Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors.

Infectious Diseases Hmama, Zakaria Grant 58,500 CIHR: New Investigator Award (CIHR Scholarship)

Cell signaling regulating mycobacterial-macrophage interactions

Infectious Diseases Hmama, Zakaria Grant 22,500 BC Lung: Project Grant Mycobacterial factors that inhibit phagosomal maturation in the macrophageInfectious Diseases Lee, Jimmy Grant 2,000 MSFHR: Doctoral Trainee

Research Award # 57(02-1)BM Role of Distinct P13-Kinase Isoforms in Regulating Phagocytosis and Phagsome Maturation.

Infectious Diseases Montaner, Julio Clinical Trial 27,283 CIHR/Rx&D: Research Program - Clinical Trials DCT-48206

An OpenLabel, Randomized Study to Evaluate the Antiretroviral Effect, Tolerability, Safety and Pharmakonitecs of Squinavir SGC/Ritonavir QD vs. Indinavir/Norvir BID in HIV Infected Patients

Infectious Diseases Montaner, Julio Clinical Trial 32,900 CIHR/Rx&D: Research Program - Clinical Trials DCT-51595

Randomized, open-label study of continued stavudine vs. abcavir substitution with or without riboflavin and thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy.

Infectious Diseases Nandan, Devki Grant 43,667 MRC: Operating Grant MOP 38005

Molecular Mechanism of Leishmania Pathogenesis

Infectious Diseases Reiner, Neil Grant 10,000 VPR Research Development Fund

CFI proposal funding: Network biology of infections and immunity

Infectious Diseases Reiner, Neil Contract 11,500 Various Companies Infectious Diseases shared services donations Health SciencesInfectious Diseases Reiner, Neil Grant 1,315 MRC/PMAC: Health Program M. tuberculosis effects on macrophage signaling & phagolysosome fusionInfectious Diseases Reiner, Neil Grant 15,000 BC Ministry of Advanced

Education, Training and Technology

Therepeutic antibody creation for Leishmania EF-1A protein

Infectious Diseases Reiner, Neil Grant 123,147 CIHR: Operating Grant MOP-8633

Monocyte Cell Regulation

Infectious Diseases Reiner, Neil Grant 88,140 BCRICWH: Investigator Establishment Award: Richard Stokes

Establishment Award: Dr. Richard Stokes

Infectious Diseases Reiner, Neil Grant 30,000 VHHSC: Scholar Award: Cherkasov, Artem

Bioinformatics study of microbial pathogens

Infectious Diseases Reiner, Neil Grant 30,000 BC Lung: Project Grant Identification of novel mechanisms of tuberculosis pathogenesis using two-hybrid screening

Infectious Diseases Rekart, Michael Grant 1,048,328 CIDA STI/HIV/AIDS Prevention and care in southern VietnamInfectious Diseases Steiner, Theodore Grant 192,845 BWF: Career Awards in the

Biomedical Sciences 992840.01Isolation and characterization of an interleukin-8-releasing protein from enteroaggregative Escherichia coli

UBC Department of Medicine 4 Annual Report 2002




Infectious Diseases Steiner, Theodore Grant 249,344 CFI UBCLOI: New Opportunities # 4453

Laboratory of Microbial Pathogenesis and Host Interaction

Infectious Diseases Stiver, Grant Grant 1,500 BCHRF: Studentship ST#51(99) The relations between Illness Beliefs, Coping, Social Support, and Outcomes in the Chronic Fatigue Syndrome

Infectious Diseases Stiver, Grant Contract 39,694 Various Pharmaceutical Companies AI411-227

The Safety and Efficacy of Cefepime versus Ceftriaxone in the Treatment of Non-hospital Acquired Pneumonia in the Elderly

Infectious Diseases Stiver, Grant Grant 10,000 VHHSC: Interdisciplinary Grant The Economic Burden of Chronic Illness: A Comparison of Chronic Fatigue Syndrome and Rheumatoid Arthritis

Infectious Diseases Tyndall, Mark Grant 36,446 CIHR Feasibility study for a safe injection facility in the downtown eastside of VancouverInfectious Diseases Tyndall, Mark Grant 200,000 VCHA Community Health and Safety Evaluation ProjectInfectious Diseases Tyndall, Mark Grant 200,000 Ontario HIV Network (OHTN) Post marketing surveillance of adverse events due to antiretroviral therapyMedical Oncology Bally, Marcel Grant 108,740 NCIC Combining conventional therapeutics with molecular targeting strategies for the treatment of breast

cancerMedical Oncology Chi, Kim Agreement 400,302 US Army DAMD17-02-0226,

PC011011 A Phase 1/11 study of combination neoadjuvant hormone therapy and weekly OGX-011 (Clusterin Antisense Oligonucleotide) prior to radical prostatectomy in patients with prostate cancer

Medical Oncology Chi, Kim Grant 50,000 Prostate Cancer Research Foundation of Canada

Randomized Phase II Trial of Strontium-89 with or without Cisplatin for the Palliation Bone Pain Secondary to Hormone Refractory Prostate Cancer

Medical Oncology Chi, Kim Grant 400,302 NCIC Canadian Cancer Society A phase1/11 study of a second generation antisense oligonucleotide targeted to clusterin (OGX-011) in combination with doetaxel

Medical Oncology Chi, Kim Clinical Trial 60,000 Ontogen Pharmaceuticals Phase I and pharmacokinetic Study of OC1144-093 and paclitaxel in advanced cancerMedical Oncology Chia, Stephen Grant 117,500 National Cancer Institute of

CanadaCanadian Breast Cancer Initiative for the assessment and validation of new and novel prognostic and predictive markers in breast cancer with tissue microarrays

Medical Oncology Chia, Stephen Grant 112,000 National Cancer Institute of Canada

National Cancer Institute of Canada for the combination of conventional therapeutics with molecular targeting strategies for the treatment of breast cancer

Medical Oncology Chia, Stephen Grant 116,130 CBCRI Assessment and validation of new and novel prognostic and predictive factors in breast cancer with tissue microarrays

Medical Oncology Chia, Stephen Clinical Trial 40,000 Hoffman La Roche A Phase II trial of Caelyx and Herceptin in women with advanced or metastatic breast cancer

Medical Oncology Courneya. Kerry Grants 172,231 CBCRI Comparison of aerobic versus resistance exercise training in enhancing quality of life in early stage breast cancer patients receiving chemotherapy

Medical Oncology Gelmon, Karen Clinical Trial 40,000 NCIC - CTG IND 130 Phase I Study of T900607 given once every 3 weeks in patients with advanced cancer.Medical Oncology Gelmon, Karen Clinical Trial 40,000 NCIC - CTG IND 131 Phase I Study of Docetaxel and ZD0473 given every 3 weeks in patients with advanced cancer

Medical Oncology Gelmon, Karen Clinical Trial 20,000 NCIC - CTG IND 133 Phase I Study of NX211 and Cisplatin in Solid TumoursMedical Oncology Gelmon, Karen Clinical Trial 20,000 NCIC - CTG MA24 Phase III Trial of Three weekly Herceptin given after standard Adjuvant Therapy in HER2

Overexpressing Breast Cancer randomizing to no therapy, one year or two years of Herceptin

Medical Oncology Shenkier, Tamara Clinical Trial 30,000 CTG MAI7 Randomized Trial of Letrozole vs Placebo in women after 5 years of Tamoxifen

Medical Oncology TJ Whelan & IJ Andrulis Grants 1,166,000 CBCRI Discovery and use of clinically relevant molecular changes in breast cancer





Medical Oncology Weir, Lorna Clinical Trial 30,000 NSABP B 34 A Randomized Trial of Placebo Vs Clodronate in early breast cancer

Nephrology Keown, Paul Clinical Trial 27,429 Wyeth-Ayerst Canada Inc Investigation of Immune Response Gene Polymorphisms in Rheumatoid ArthritisNephrology Keown, Paul Agreement 8,021 Immunex Corporation Service Contract - Pharmacokinetic Modeling of the use of a Micro-emulsion formulation of

cyclosporine in a pharmacoepidemiologic trial.Nephrology Landsberg/Gill Grant 45,000 Kidney Fdn: Biomedical

Scholarship The humoral immune response in kidney allograft rejection

Nephrology Landsberg/Gill Grant 50,000 Kidney Fdn: Biomedical Scholarship

The humoral immune response in kidney transplant rejection

Nephrology Landsberg, David Clinical Trial 25,000 Fujisawa FKC-008 The Effects of Treatment of Subclinical rejection on renal histology and graft function in renal transplant patients receiving Tacrolimus and Mycophenolate Mofetil

Nephrology Landsberg, David Clinical Trial 45,000 Roche The use of Daclizumab (Zenapax) and Mycophenolate Mofetil (CellCept) in Combination with Corticosteroids and Cyclosporine (Low Dose versus Withdrawal) to Optimize Renal Function in Recipients of Renal Allografts

Nephrology Landsberg, David Clinical Trial 23,000 Novartis European Multicentre, Randomized, Double-Blind, Placebo Controlled Study of the Long Term Effects of Fluvastatin (Lescol) on Major Adverse Cardiac Events (MACE) and Progression of Chronic Transplant Dysfuntion in Renal Transplanted Patients.

Nephrology Landsberg, David Clinical Trial 7,100 Novartis CRAD001 1A1-1 year multicenter, single arm, open label, pilot study of the efficacy and safety of RAD in de novo renal transplant recipients at immunological high risk of rejection (Extension)

Nephrology Landsberg, David Clinical Trial 25,700 Wyeth-Ayerst Sirolimus 306: An open-Label Extension of the Safety of Long Term Administration of Sirolimus (Rapamune) in Solid Organ Transplant

Nephrology Landsberg, David Clinical Trial 18,700 Wyeth-Ayerst Sirolimus 310: A Randomized, Open-Label Study of Continuous Therapy with Cyclosporine and Sirolimus Versus Induction with Cyclosporine and Sirolimus Followed by Continuous Therapy with Sirolimus in Renal Allograft Recipients

Nephrology Landsberg, David Clinical Trial 10,250 Wyeth-Ayerst Sirolimus 316: A Randomized, open-label, comparative evaluation of conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment versus continued Calcineurin inhibitor treatment in renal allograft recipients

Nephrology Levin, Adeera Clinical Trial 9,631 Janssen-Ortho Inc. A study to determine the impact of Hgb maintenance and other interventional strategies to prevent or delay the progression of left ventricular mass growth in subjects with early renal insufficiency

Nephrology Levin, Adeera Grant 55,291 Various Sources NERCNephrology Levin, Adeera Clinical Trial 9,417 Amgen, Inc. An open-label study of the long-term safety of novel erythropoiesis stimulating protein (NESP)

therapy in subjects with chronic renal failure who were participants in previous NESP clinical trials

Nephrology Levin/Stevens Grant 45,000 Kidney Fdn: Biomedical Fellowship

The relationship of abnormalities in mineral metabolism to cardiovascular disease in end stage renal disease

Nephrology Levin/Stigant Grant 45,000 Kidney Fdn: Biomedical Fellowship

C-Reactive protein levels and vascular access thrombosis in chronic hemodialysis patients

Nephrology Levin, Adeera Grant 80,000 Kidney Foundation of Canada Care prior to dialysis: A multicentre prospective cohort study in renal insufficiency to assess the impact of elements of care on patient outcomes (CREDA)





Nephrology Levin, Adeera Clinical Trial 764 Ortho Biotech Effect of early correction of anemia on the progression of chronic renal failure (ECAP) DNA sub-study

Nephrology Levin, Adeera Clinical Trial 6,463 AMGEN Canada Inc. A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of a calcimimetic agent (AMG 073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency

Nephrology Levin, Adeera Clinical Trial 2,271 AMGEN Canada Inc. A study evaluating the initiation titration of fixed doses of nevel erythropoiesis stimulating protein (NESP) therapy in subjects with end-stage renal disease

Nephrology Levin, Adeera Clinical Trial 1,337 Janssen-Ortho Inc. Double blind study to assess the impact of normalizatin of hemoglobin compared to partial correction of hemoglobin with eprex/erypo erythropoietinin early hemodialysispatients (RWJ-22512)

Nephrology Quamme, Gary Grant 175,000 CIHR: Operating Grant # MOP-53288

Studies of Renal Magnesium Transport.

Nephrology Shapiro, Jean Clinical Trial 50,600 BC Health Research Foundation/Michael Smith Foundation

A Prospective, Randomized, Double-Blind, Placebo Controlled Study of Alendronate in the Treatment of Osteoporosis in first Kidney or Kidney/Pancreas Transplantation

Nephrology Shapiro, Jean Clinical Trial 20,000 Fujisawa FKC 003: TACROLIMUS: Tacrolimus as Secondary Intervention vs continuation of CsA in Patients at Risk for Chronic Renal Allograft Failure

Nephrology Shapiro, Jean Clinical Trial 20,000 Fujisawa Therapeutic Drug Monitoring for Tacrolimus in Kidney and Kidney-Pancreas Transplant Recipients

Nephrology Shapiro, Jean Clinical Trial 65,000 Fujisawa FKC-008 The Effects of Treatment of Subclinical rejection on renal histology and graft function in renal transplant patients receiving Tacrolimus and Mycophenolate Mofetil

Nephrology Shapiro, Jean Clinical Trial 4,600 Novartis ERL080A. Multicentre, Double-Blind, Randomized, Parallel Group Study on Tolerability and Safety of ERL080A vs Mycophenolate Mofetil (CellCept) in Maintenance Renal Transplant Patients

Nephrology Shapiro, Jean Clinical Trial 12,000 Bristol Myers Squibb Open Label Randomized, controlled, multiple dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in renal transplant recipients

Nephrology Quamme, Gary Grant 175,000 CIHR: Operating Grant # MOP-53288

Studies of Renal Magnesium Transport.

Nephrology Wong, Norman Grant 67,743 H&SFBC: Research Effects of endothelin in congestive heart failureNephrology Wong, Norman Grant 63,390 Canadian Apoptosis Research

Foundation Accelerated neuronal aging caused by transient exposure to toxin.

Neurology Calne, Donald Grant 409 Donation for Health Science Research

Parkinson's Disease Research

Neurology Calne, Donald Contract 41,054 US Natl Parkinson Fdn: Research National Parkinson Foundation, Centre of Excellence.

Neurology Calne, Donald Contract 3,946 US Natl Parkinson Fdn: Research National Parkinson Foundation, Centre of Excellence.

Neurology Calne, Donald Grant 228,631 Various sources 16-017292-7 Movement Disorder ClinicNeurology Calne, Donald Grant 116,648 MRC: Operating Grant Studies on the natural history and etiology of sporadic Parkinson's diseaseNeurology Calne, Donald Grant 48,716 MRC: Group Grant MGC 36035 DDMP Core A: Biomedical Mathematical Core





Neurology Calne, Donald Grant 12,000 Parkinson Foundation of Canada Clinical Community Assistance Program

Neurology Doudet, Doris Agreement 27,258 Titan Pharmaceuticals Inc. Effects of striatal implantation of RPE cells in a rodent model of Parkinson's DiseaseNeurology Doudet, Doris Contract 133,407 Titan Pharmaceuticals Inc. In vivo PET study of the effects of striatal implantation of Retinal Pigment Epithelial Cells in a

primate model of Parkinson's DiseaseNeurology Doudet, Doris Grant 104,518 MRC: Group Grant MOP-14535 DDMP Project 10: In vivo study of the effects of manipulations on the dopaminergic synapse by

PETNeurology Doudet, Doris Grant 59,077 MRC: Operating Grant MOP

36361In vivo study of the effects of electroconvulsive therapy on the dopaminergic system by position emission tomography

Neurology Eisen, Andrew Clinical Trial 16,140 Sanofi Canada Inc Long term safety and tolerability study of SR57746A in patients with Amyotropic Lateral Sclerosis

Neurology Eisen, Andrew Grant 470 Donations for Health Science Research

General Neurology Research

Neurology Eisen, Andrew Clinical Trial 11,940 Various Pharmaceutical Companies LTS 3069, EFC 2491

Clinical Trials

Neurology Feldman, Howard Clinical Trial 181,232 GlaxoSmithKline Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheiners Disease: the GenAda Study Protocol ALDHD2001/00013/00

Neurology Feldman, Howard Grant 90,477 ASC/Astra/CCNS/CIHR: Alzheimer Disease Biomedical Res. Grant 02-49

A serial magnetic resonance study of cognitively-impaired-not demented patients and controls

Neurology Feldman, Howard Contract 65,000 Various Pharmaceutical Companies

A Cohort Study of Cognitive Impairment and Dementia Syndromes with the Development of a Consortium Registry.

Neurology Feldman, Howard Contract 40,000 Various Pharmaceutical Companies

UBC: A Cohort Study of Cognitive Impairment and Dementia Syndromes with the Development of a Consortium Registry.

Neurology Feldman, Howard Clinical Trial 48,100 Janssen-Ortho Inc. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with Mild cognitive Impairment (MCI) clinically at risk for clinically probable Alzheimer

Neurology Feldman, Howard Clinical Trial 31,070 Janssen-Ortho Inc. GAl-INT-6: The safety and efficacy of Galantamine in the treatment of vascular and mixed dementia

Neurology Feldman, Howard Clinical Trial 29,250 MSFHR: Postdoctoral Trainee Fellowship

Susceptibility genes and environmental risk factors for Alzheimer's disease.

Neurology Feldman, Howard Clinical Trial 18,894 University of California, San Diego

A randomized double blind, placebo controlled trial to evaluate the safety & efficacy of vitamin E and Donepezil HC1 (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer's disease.

Neurology Feldman, Howard Contract 25,000 Synapse Technologies Inc./Biomarin Pharm.Inc.

A Cohort Study of Cognitive Impairment and Dementia Syndromes with the Development of a Consortium Registry

Neurology Feldman, Howard Grant 38,638 VHHSC: VGH/UBC Fdn Special Opportunities Research Fund

A Serial Magnetic Resonance Study of Cognitively-Impaired-Not-Demented Patients and Controls

Neurology Gibson, Gillian Clinical Trial 20,000 Eli Lilly Canada Inc. Protocol B7A-MC-MBCW: LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes





Neurology Gibson, Gillian Clinical Trial 8,042 Bayer Inc. A Canadian Multicenter Randomized Double-Blind Controlled Study to Compare the Effects of Different Dose Regimens of IVIG-S/D 10% in Patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Neurology Gibson, Gillian Clinical Trial 20,000 Eli Lilly Canada Inc. Protocol B7A-MC-MBBR: LY333531 Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial

Neurology Hashimoto, Stanley Clinical Trial 1,513 Biogen Inc. C98-838 An open label safety extension study of AVONEX (Interferon Beta-la) treatment in subjects who completed Biogen studies C95-812, C96-823 or C97-830

Neurology Hooge, John Clinical Trial 16,554 Ares-Serono International Inc. 21125, BB-IND 5371

An open label, randomized, multicentre, comparative, parallel group study of Rebit 44mcg administered three times per week by subcutaneous injection, compared with Avonex 30msg administered once per week by intramuscular injection.

Neurology Hsiung, Ging-Yuek Grant 29,250 MSFHR: Postdoctoral Trainee Fellowship 117(02-01) BM

Susceptibility genes and environment risk factors for Alzheimer's disease.

Neurology Johnston, Dean Grant 7,500 Canadian Stroke Network Canadian Stroke RegistryNeurology Jones, Michael Clinical Trial 21,220 Warner-Lambert Canada Inc. Pregabalin ann-on trial: A double blind, placebo controlled, multicentre study in patients with partial

seizures. 1008-009Neurology Jones, Michael Clinical Trial 7,993 UCB Pharma A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and

safety of adjunctive treatment with 3000 mg/day(pediatric target dose of 60mg/kg/day)oral levetiracetam (LEV) (166,250,and 500 mg tablets).....

Neurology Jones, Michael Clinical Trial 9,834 Pfizer Canada Inc. Protocol 1008-114-141: Pregabalin Open-Label Add-On Trial: An Open-Label Multicentre Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures

Neurology Jones, Michael Clinical Trial 9,002 Pfizer Canada Inc. Protocol 1008-157-181: Pregabalin BID Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures

Neurology Jones, Michael Clinical Trial 6,102 Pfizer Canada Inc. Protocol 1008-164: Pregabalin BID Open-Label, Add-On Trial: A Follow-On Study To Determine Long-Term Safety and Efficacy in Patients with Partial Seizures

Neurology Jones, Michael Clinical Trial 8,800 Pfizer Canada Inc. Pregabalin BID Add-On Trial: A Randomized, Double-Blind, Parallel-Group, Placebo and Lamotrigine-Controlled, Multicenter Study in Patients with Partial Seizures.

Neurology Kastrukoff, Lorne Clinical Trial 125,787 Teva Marion Partners 9008 PROMISE - A multi national, multicentre double blind, placebo controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate in Primary Progressive Multiple Sclerosis

Neurology Kastrukoff, Lorne Grant 400 Donations for Health Science Research

Virology Research

Neurology Krieger, Charles Grant 30,000 VHHSC Clinical Investigator Award: Charles Krieger

Modulation of Neuron Death by Protein Kinase C and Calcineurin in Amyotrophic Lateral Sclerosis.

Neurology Lee, Chong Grant 30,000 Pacific Parkinson's Research Institute

Mechanisms of levodopa-induced dyskinesia: Role of dopaminergic denervation

Neurology Lee, Chong Grant 49,780 CIHR: Operating Grant Studies on mechanisms of dyskinesia induced by pulsatile treatment with levodopaNeurology Lee, Chong Grant 116,648 MRC: Operating Grant Studies on the natural history and etiology of sporadic Parkinson's diseaseNeurology Oger, Joel Clinical Trial 47,051 Angiotech Pharmaceuticals Inc.

006-MPMS99A double blind randomized, placebo controlled multicentre Phase 2 clinical study using micellar paclitaxel in patients with secondary progressive multiple sclerosis.





Neurology Oger, Joel Clinical Trial 10,998 Biogen Inc. C98-844 A Multicentre Open Label Antigenicity and Safety Study of a Human Serum Albumin-Free Pre Formulated Solution of AVONEX (Interferon beta-1a) Administered Intramuscularly to Patients with Relapsing Multiple Sclerosis

Neurology Oger, Joel Clinical Trial 195,781 Aventis Pharmaceuticals Inc. HMR 1726D/2001

1) Phase II study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis with relapses.2) Evaluation of in-Vitro Cell Adhesion in MS Patients, Effect of Treatment with Teriflunomide (Sub-Study).

Neurology Oger, Joel Clinical Trial 119,121 Biogen, Inc C-1801 C-1801: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Safety and Efficacy of Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis.

Neurology Oger, Joel Clinical Trial 18,751 Berlex Canada Inc. Double-Blind Placebo-Controlled Randomized Parallel Group Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of 8 MIU Interferon Beta-1B (Betaseron) in Patients with a First Demyelinating Event Suggestive of MS

Neurology Oger, Joel Clinical Trial 31,946 Biogen Inc. Protocol C-862: Multicentre Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif to Determine the Efficacy Tolerability and Safety in Subjects with Relapsing Multiple Sclerosis

Neurology Oger, Joel Grant 4,567 Myasthenia Gravis Association of BC

Studentship: Predictors of prognosis in myasthenia gravis: a multicentre retrospective analysis

Neurology Oger, Joel Contract 64,000 Biogen, Inc Clinical fellowship for Dr. Penelope SmythNeurology Oger, Joel Clinical Trial 214,153 Ares-Serono International Inc. #

22930Protocol #22930 follow-up study: Long-term efficacy and safety phase IV follow-up of the Prisms cohort

Neurology Oger, Joel Grant 2,339 Donations for Health Science Research

Myasthenia Gravis Research

Neurology Oger, Joel Grant 6,009 Donation Neuro-Immunology ResearchNeurology Oger, Joel Grant 36,000 MSSC: Postdoctoral Fellowships MSSC Postdoctoral Fellowship - Dr. Helen Tremlett

Neurology Oger, Joel Clinical Trial 1,957 Teva Neuroscience, GP Multinational multicentre randomized, double blind, placebo controlled study to evaluate the efficacy, tolerability & safety of 2 doses (5mg and 50Mg) of Glatiramer acetate orally administered in relapsing remitting multiple sclerosis pts

Neurology Paty, Donald Contract 2,125,603 Various Sources MRI Analysis for Protocols 6789 and 6954Neurology Paty, Donald Contract 3,077,775 Various Sources MRI Analysis for Protocol #7999 (original)Neurology Paty, Donald Contract 15,598 Various Pharmaceutical

CompaniesH. Feldman: Brain Research Centre - Clinical Investigator Award

Neurology Paty, Donald Contract 2,360,003 Serono Laboratories Inc. IMP 21125 "An open label, randomized, multicenter, comparative study of Rebif 44 mcg admin. 3x/week, compared with Avonex 30 mcg admin. 1x/week by intramuscular injection on the treatment of relapsing-remitting Multiple Sclerosis"

Neurology Paty, Donald Contract 574,368 Angiotech Pharmaceuticals Inc. UBC MS/MRI Research Group Service Agreement for Angiotech Study 006-MPMS99

Neurology Pelech, Steven Grant 81,712 MRC: Operating Grant MOP 38062

MAP kinase pathways in seastar oocyte cell cycle control

Neurology Ruth, Thomas Grant 1,287,500 CFI: Innovation Projects Functional Imaging in basic biomedical research





Neurology Ruth, Thomas Grant 25,830 MRC: Group Grant MT - 14535 DDMP Project 10: In vivo study of the effects of manipulations on the dopaminergic synapse by PET

Neurology Ruth, Thomas Grant 516,368 MRC: Group Grant MGC 36035 DDMP Core B: Positron Emission TomographyNeurology Ruth, Thomas Grant 57,361 MRC: Multi-User Maintenance

GrantMRC: Multi-User Maintenance Grant MR-11806

Neurology Stoessl, Jonathan Clinical Trial 27,820 Aventis Pharmaceuticals Inc. A Phase III multicentre, double blind, parallel group, placebo controlled study of the effects of Riluzole 50mg bid of 100mg bid for 2 years on the progression of Parkinsons Disease in 1050 patients.

Neurology Stoessl, Jonathan Clinical Trial 26,169 Kyowa Pharmaceutical, Inc 6002-US-005

6002-US-005: A 12 Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy or 40mg/day KW-6002 as Treatment for Parkinsons's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy

Neurology Stoessl, Jonathan Clinical Trial 26,915 Smithkline Beecham Pharma Inc. (Canada) 101468/170

A non-interventional follow-up study to observe the long term outcome of Parkinson's Disease in patients who completed study SK & F 101468/056 or study SK&F 101468/125 (STUDY 101468/170)

Neurology Stoessl, Jonathan Grant 384,148 CFI: Canada Research Chairs Molecular Imaging of the Nervous System in VivoNeurology Stoessl, Jonathan Grant 3,958 MRC: Fellowship MFE 35385 Studies on fluctuations in response to dopaminergic therapyNeurology Stoessl, Jonathan Grant 45,000 Parkinson Society Canada

Wherrett FellowshipParkinson Society Canada: Fellowship for Dr. Zhigao Huang

Neurology Stoessl, Jonathan Grant 56,766 MRC: Group Grant MT-14751 DDMP Project 11: Pharmacological studies in experimental models of dyskinesiaNeurology Stoessl, Jonathan Grant 110,467 MRC: Operating Grant MT -

15126 Studies on fluctuations in response to dopaminergic therapy

Neurology Stoessl, Jonathan Grant 646,708 MRC: Group Grant MGC 36035 Degenerative Disorders of the Motor PathwaysNeurology Stoessl, Jonathan Grant 200,000 Canada Research Chair Tier I

(CIHR)Canada Research Chair - A. Jon Stoessl

Neurology Stoessl, Jonathan Agreement 68,578 NIH (US): Research Grant Double Blind Controlled Trial of Nigral Grafting in PDNeurology Teal, Phillip Clinical Trial 7,230 Parke-Davis Pharmaceuticals A double blind randomized, placebo controlled study of Atorvastatin as prevention of

Cerebrovascular events in patients with a previous transient Ischemic Attack (TIA) or stroke.

Neurology Teal, Phillip Clinical Trial 41,004 Pfizer Canada Inc. A Double-Blind, Placebo Controlled, Multi-Center Adaptive Design Study to Assess The Dose-Response Relationship, Safety and Toleration Of UK-279,276 In Acute Stroke

Neurology Teal, Phillip Clinical Trial 132,434 Bayer Inc. A randomized double-blind, placebo-ctonrolled trial to Evaluate the efficacy, safety, tolerability, and pharmacokinetic/Pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke.

Neurology Teal, Phillip Clinical Trial 98,206 Wake Forest University - School of Medicine

Vitamin Intervention for Stroke Prevention

Neurology Teal, Phillip Clinical Trial 9,796 Eli Lilly Canada Inc. Abciximab (ReoPro) in Acute Ischemic Stroke: A randomized, double-blind, placebo-controlled trial.

Neurology Teal, Phillip Clinical Trial 20 Eisai America Inc A 24 week multicenter, randomized, double blind, palcebo controlled evaluation of the Efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease





Neurology Teal, Phillip Clinical Trial 63,777 Yamanouchi USA Inc. ARTIST: A Multicentre Stratified Randomized Double-Blind Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Acti

Neurology Teal, Phillip Clinical Trial 5,850 Sanofi-Synthelabo Recherche MATCH EFC7331: Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Transient Ischemic Attack or Ischemic Stroke.

Neurology Teal, Phillip Clinical Trial 55,302 University of Ottawa The Registry of the Canadian Stroke Network

Neurology Teal, Phillip Clinical Trial 20,940 ONO Pharma USA, Inc 2506/INT0104: Randomized Double-Blind Placebo-Controlled Multi-Centre Study of the Effects of ONO-2506 IV Infusion on the Amelioration of Neurological Damage & Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic St

Neurology Teal, Phillip Clinical Trial 4,000 Sanofi-Synthelabo Canada Inc Protocol EFC4505: (CHARISMA) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

Neurology Tsui, Joseph Clinical Trial 3,979 Cyberonics Inc A pilot safety and efficacy study of Vagus Nerve (VNS) using the NeuroCybernetic Prosthesis (NCP) System in patients with severe, disabling tremor.

Neurology Tsui, Joseph Clinical Trial 57,425 Elan Pharmaceuticals Inc. AN072-401CD

An Open Label Safety and Immunogenecity Study of MYOBLOC (NEUROBLOC; BOTULINIM TOXIN TYPE B) Injectable Solution in Patients with Cervical Dystonia.

Neurology Tsui, Joseph Clinical Trial 18,662 Novartis Pharmaceuticals Canada Inc.# CTCH346 0103

CTCH346 0103: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg & 20 mg daily) in Patients with Early Parkinson's Disease.

Neurology Tsui, Joseph Clinical Trial 34,868 MERCK (Germany) Protocol EMR 62 225-006: Multicentre Multinational Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Finding Study to Investigate the Anti-Dyskinetic Efficacy & Safety of Sarizotan in Parkinson Patients with L-dopa-induced Dysk

Neurology Tsui, Joseph Grant 41,039 MRC: Operating Grant MGP-15583

Occupational Risk Factors in Parkinson's Disease

Neurology Wang, Yu Tian Grant 600 CIHR: Doctoral Research Awards DD5 61947

Ampar trafficking in models of cerebral ischemia

Neurology Wang, Yu Tian Grant 11,000 MSFHR: Postdoctoral Trainee Fellowship

Modulation of ligand-gated receptors by G protein-coupled receptors

Neurology Wong, Milton Contract 20,000 Hoffmann-La Roche Canadian Activase for stroke effectiveness study (Cases)Neurology Woolfenden, Andrew Grant 23,111 University of Cincinnati Interventional Management of Stroke (IMS) StudyNeurology Woolfenden, Andrew Clinical Trial 18,403 Emory University Hospital Warfarin Aspirin symptomatic intractranial disease (WASID) studyPhysical & Rehab Med Dawson, Drew Clinical Trial 230,000 CIHR Postural Control in StrokePhysical & Rehab Med Dawson, Drew Clinical Trial 73,480 Heart & Stroke Foundation 6 Week Training Program in StrokePhysical & Rehab Med Dhawan, Pankaj Clinical Trial 19,913 Neurostream Technologies, Inc Observational: How Stroke Patients Walk

Physical & Rehab Med Dhawan, Pankaj Clinical Trial 38,825 Neurostream Technologies, Inc The Gait Observational Study

Physical & Rehab Med Hirsch, Gabriel Clinical Trial 28,525 Biomotion Technologies Ltd. Multi-center Prospective Study to assess the Walk-Aide 2Physical & Rehab Med Hughes,Barbara Clinical Trial 10,346 ACORDA Therapeutics SCI-F300: Double-Blind, Placebo-Controlled, 4 Week Parallel Group Study to Evaluate Safety and

Efficacy of Oral Fampridine-SR in Subjects with Moderate to Severe Spasticity Resulting from Chronic, Incomplete Spinal Cord Injury





Physical & Rehab Med Hughes,Barbara Clinical Trial 15,000 BC Rehab Foundation Long Term Follow-UP and Prospective Study of Patients Fitted with Lower Extremity Braces for Paraplegic Brace Walking at GF Strong Rehabilitation Centre

Physical & Rehab Med Mortifee, Peter Contract 2,000 Merck Frosst "National Survey of Canadian Physiatrists, Part I: Demographics, Practice Profiles and Computer Use" and National Survey of Canadian Physiatrists, Part 2: Continuing Professional Development, Perceived Usefulness, and Learning"

Physical & Rehab Med Hughes,Barbara Clinical Trial 2,200 NSERC Comparison of Spinergy Wheels vs Std. Steel Spoke Wheelchair WheelsPhysical & Rehab Med Travlos, Andrew Clinical Trial 21,600 Amyotrophic Lateral Sclerosis

Association (USA)The Impact of Enteral Nutritional Support on the Quality of Life of ALS patients and Their Primary Care-Givers

Physical & Rehab Med Travlos, Andrew Clinical Trial 2,500 BC Rehab Foundation Viability of Sip and Puff Switch Use with ALS Clients with Impaired Speech and Swallowing

Physical & Rehab Med Underwood, Heather Clinical Trial 15,000 BC Rehab Foundation The Effects of Prosthetic Alignment and Interface Materials in Minimizing Foot Pressure with Rotionalplasty Prostheses

Physical & Rehab Med Weeks, Claire Clinical Trial 26,000 ICORD International Evaluation of the 3rd Version of the SC Independence MeasurePhysical & Rehab Med Weeks, Claire Clinical Trial 6000 VHHSC Interdisciplinary Grant Pain Following Spinal Cord Injury: Client Perspectives and General Practitioners AttitudesRespiratory Abboud, Raja Clinical Trial 10,752 Smithkline Beecham Pharma Inc.

(Canada)A multicenter, open label extension study to evaluate the safety tolerability and efficacy of oral ariflo (15mg twice daily) in patients with chronic obstructive pulmonary disease (COPD).

Respiratory Abboud, Raja Grant 30,000 BC Lung: Research Grant Relationship of genetic polymorphism in alveolar macrophage metallopreteases to the development of emphysema in smokers

Respiratory Abboud, Raja Contract 137,066 Glaxo Group Research Limited, UK

Genetic polymorphisms in alveolar macrophage metalloproteases and the development of emphysema in smokers.

Respiratory Abboud, Raja Clinical Trial 22,382 Boehringer Ingelheim (Canada) Ltd

Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study)

Respiratory Ayas, Najib Grant 22,083 CIHR: New Investigator Award (CIHR Scholarship) JBH-56261

Investigation of the diagnosis and treatment of sleep disordered breathing

Respiratory Ayas, Najib Grant 10,000 BC Lung: Career Development Award

Career Development Award

Respiratory Ayas, Najib Grant 10,000 Academic Enhancement FundRespiratory Ayas, Najib Grant 29,900 BCLA Operating Grant The Societal Consequences of Sleep apneaRespiratory Ayas, Najib Grant 18,750 BC Lung/CIHR Investigator Investigation of the diagnosis and treatment of sleep disordered breathingRespiratory Bai, Tony Grant 81,302 CIHR: Operating Grant MOP-

42537Modulation of airway function by neurotrophic cytokines

Respiratory Bai, Tony Clinical Trial 3,000 Intermune Pharmaceuticals, Inc. An open-label study of the safety and efficacy of subcutaneous recombinant interferon gamma-1b (IFN-y1b) in patients with idiopathic pulmonary fibrosis

Respiratory Chan-Yeung, Moira Grant 30,000 BC Lung: Project Grant Indoor aeroallergen and endotoxin levels and asthma symptoms in a birth cohort of high risk children at age 6-7 years following a randomized controlled intervention study on the primary prevention of asthma.

Respiratory Chan-Yeung, Moira Grant 8,895 MRC: Operating Grant Candidate genes for asthma and atopy in a cohort of at risk infantsRespiratory Chan-Yeung, Moira Grant 93,274 CIHR: Operating Grant MOP-

49479Follow-up Study of a High Risk Birth Cohort Folllowing a Ramdomized Controlled Intervention Study on the Primary Prevention of Asthma.





Respiratory Chan-Yeung, Moira Grant 3,426 Donations for Health Science Research

A multicentre study to determine the effectiveness of a multifaceted intervention program to prevent the development of asthma in high risk infants

Respiratory Duronio, Vincent Grant 118,867 NCIC: Research 012332 Role of bad and mcl-1 in apoptosis, survival and cell differentiationRespiratory Duronio, Vincent Grant 32,500 MRC/BC Lung Assn Scholarship

& Scientist Award SB-21718-AP008874, 32448

Signalling pathways and second messengers regulating myeloid cell growth and survival

Respiratory Duronio, Vincent Grant 32,500 BC Lung/CIHR Investigator Signalling pathways and second messengers regulating myeloid cell growth and survivalRespiratory Duronio, Vincent Grant 51,250 MSFHR: Senior Scholar Award

70(CI-2001)Key Signalling Pathways Controlling Survival and Death of Hemopoietic Cells

Respiratory Duronio, Vincent Grant 32,500 MRC/BC Lung Assn Scholarship & Scientist AwardSB-21718-AP008874,32448: Vincent Duronio

Signalling pathways and second messengers regulating myeloid cell growth and survival.

Respiratory Duronio, Vincent Grant 22,500 BC Lung Project Grant Investigation of the P13-kinase Signalling Pathway in Human Lung Cancer as a Potential Mediator of Oncogenesis

Respiratory Duronio, Vincent Grant 35,000 H&SFBC: Research Fellowship Cell Survival of Macrophages by Oxidized ldl is by a p13k Dependent Pathway in Atherosclerosis.

Respiratory Duronio, Vincent Grant 52,000 Cancer Research Society: Research Grant

Functions of Bad Controlled by Phorphorylation at a novel site

Respiratory Duronio, Vincent Grant 28,500 NCE/Protein Engineering: Research

Pence P3 Post2

Respiratory Duronio, Vincent Grant 2,500 MSFHR: Masters Trainee Research Award 112-BM

Regulation of Bci-2 Family Members Involved in Macrophage Cell Survival

Respiratory Duronio, Vincent Grant 119,354 CIHR Operating Grant Cytokine regulated signalling pathways in inflammatory cellsRespiratory Fitzgerald, Mark Clinical Trial 8,500 Boehringer Ingelheim Ltd.

352.2028RUSIC A Prospective Study to Quantify the Effects of COPD Exacerbation on the Health Care Resource Utilization of COPD Patients.

Respiratory Fitzgerald, Mark Clinical Trial 1,390 AstraZeneca Canada Inc.SD-039-0668

(STEP) Efficacy & Safety of Symbicort (Budesonide/fermoterol) Turbuhaler as a Single Therapy in Patients with Moderate-Severe Asthma. Comparison with Conventional Asthma Therapy, Pulmicort (Budesonide) Turbuhaler.

Respiratory Fitzgerald, Mark Clinical Trial 3,555 AstraZeneca Canada Inc.DC-039-0001

SMART: The Effectiveness and Safety of an Individualized Symbicort Turbuhaler Maintenance Dosing Regimen (Symbicort Asthma Control Plan) vs. Symbicort Turbuhaler Given as a Regular Twice Daily Therapy.

Respiratory Fitzgerald, Mark Clinical Trial 7,300 Hoffman La-Roche ltd (Canada) Protocol BA 16631: Dose-Ranging Study of Ro 27-2441 in Patients With Persistent Asthma Not Treated With Inhaled Corticosteroid - Phase II

Respiratory Fitzgerald, Mark Clinical Trial 1,250 GlaxoSmithKline PACE-IMT SAS40068

Protocol SAS40068: PACE-IMT 24 Week Multicentre Randomized Double-Blind Parallel Group Trial to Compare the Efficacy & Tolerability of Salmeterol/Fluticasone Propionate Diskus Combination (Advair) 50/100 mcg bid with Fluticasone Propionate

Respiratory Fitzgerald, Mark Grant 42,000 BC Lung/CIHR Investigator Bringing evidence to the patientRespiratory Fitzgerald, Mark Grant 68,930 Healthshares Holdings, Inc Initiative for the Study and Implementation of Systems (ISIS)





Respiratory Fitzgerald, Mark Contract 233,700 Centers for Disease Control and Prevention 200-1999-00102 / 03

Tuberculosis Trials Consortium (TBTC)

Respiratory Fitzgerald, Mark Contract 75,249 Centers for Disease Control and Prevention 200-2001-00094

CDC Tuberculosis Epidemiology Study Group

Respiratory Fitzgerald, Mark Contract 320,124 Centers for Disease Control & Prevention 200-2002-00094/0002

Prospective evaluation of immunogenetic susceptibility to mycrobacterium tuberculosis infection and surrogate markers for tubercolusis infection and disease

Respiratory Fitzgerald, Mark Grant 38,500 CLA/CIHR: Partnership Challenge Fellowship

Psychological determinants of poor asthma self-management

Respiratory Fitzgerald, Mark Clinical Trial 5,498 Boehringer Ingelheim Ltd. SAFE: Spiriva Assessment of FEV1. The Effect of Inhaled Tiotopium Bromide (18 mcg Once Daily) on the Change in FEV1 and Symptoms During Long-Term Treatment in Patients with COPD. A I yr Parallell Group Double-Blind Randomized Placebo Controlled Study.

Respiratory Fitzgerald, Mark Clinical Trial 1,916 Altana Pharma, Inc. An assessment of safety and efficacy in treating moderate to severe asthmatics with inhaled ciclesonide 400ug b.i.d. (800ug/day) versus inhaled fluticasone propionate 500 ug b.i.d. (1000ug/day)

Respiratory Fitzgerald, Mark Grant 42,000 BC Lung: Fellowship Dr. Stefan Grzybowski Fellowship in Respiratory Medicine.Respiratory Fleetham, John Contract 54,003 Various Pharmaceutical

CompaniesRespiratory Division Education Fund

Respiratory Fleetham, John Grant 30,713 CIHR/BC Lung Assn: Investigator JBC-56221

Bringing evidence to the patient

Respiratory Fleetham, John Grant 6,000 CIHR University-Industry: All CIHR Programs I-14909

Multi-centre Randomized Trial of Continuous Positive Airway Pressure for the Treatment of Heart Failure Patients with Central Sleep Apnea,

Respiratory Khalil, Nasreen Contract 132,000 Glaxo Wellcome Inc (Now GLAXOSMITHKLINE)

Transforming Growth Factor-beta in Pulmonary Airway and Parenchymal Remodelling

Respiratory Khalil, Nasreen Grant 42,000 BC Lung: Fellowship Dr. Whitey Thurlbeck Fellowship in Respiratory Medicine - Dr. Ying Dong XuRespiratory Khalil, Nasreen Grant 60,000 VHHSC Scientist Award Transforming Growth Factor Beta Regulation of Pulmonary Fibrosis and Airway Remodelling.

Respiratory Khalil, Nasreen Grant 18,000 VPR Research Development Fund

Transfroming growth factor beta regulation of pulmonary fibrosis

Respiratory Khalil, Nasreen Grant 95,000 CIHR-POP Inhibition of activation of latent-transforming growth factor beta: therapeutic applicationRespiratory Khalil, Nasreen Grant 5,000 Nfld. & Labrador Lung

AssociationDistribution of TGF-beta related proteins in IPF

Respiratory Khalil, Nasreen Contract 45,000 Novartis Valsartan in models of pulmonary parenchymal and airway remodelingRespiratory Khalil, Nasreen/

Bai, TonyClinical Trial 48,248 Intermune Pharmaceuticals, Inc. A randomized, double-blind, placebo-controlled phase II study of the safety and efficacy of

subcutaneous recombinant interferon-y1b (rlFN-y 1b) in patients with idiopathic pulmonary fibrosis

Respiratory Lam, Stephen Grant 55,579 NCI-USA: Specialized Program of Research Excellence (SPORE) in Lung Cancer 1-U01-CA84971-04

Markers for Risk Assessment/Early Detection of Lung and Breast Cancer





Respiratory Lam, Stephen Contract 342,888 NCI-USA: N01-CN-85155 A Phase II Trial of Pulmicort Turbuhaler in Persons with Dysplasia of the Bronchial Epithelium

Respiratory Lam, Stephen Grant 304,872 NCIC - Terry Fox New Frontiers Initiative

Identifying Molecular Targets for Prevention and Treatment of Lung Cancer

Respiratory Lam, Stephen Grant 210,070 NIH-USA-PAS-99-010 Bioengineering Research Partnerships

Partnership for Research in Optical Coherence Tomography

Respiratory Lam, Stephen Grant 83,922 NCIC - Terry Fox New Frontiers Initiative

Confocal Microscopy with DMD-Address Fibers

Respiratory Lam, Stephen Grant 233,452 Genome BC & Genome Canada Cancer Genomics: A Multi-Disciplinary Approach to the Large Scale High-Throughput Identification of Genes Involved in Early Stage Cancer

Respiratory Lam, Stephen Contract 46,408 Numico Research BV & Global Cancer Strategies Ltd.

A Study of the Safety and Efficacy of ACAPHA in Persons with or without Bronchial Intraepithelial Neoplasia

Respiratory Lam, Stephen Grant 631,008 NCI-USA U01-CA96109-01 Phase II Trial of ACAPHA in Former Smokers wiith IENRespiratory Lam, Stephen Clinical Trial 154 Broncus Technologies, Inc. Feasibility Study of the Broncus Alair System for the treatment of asthmaRespiratory Levy, Robert/

Pare, Peter Clinical Trial 439,590 GlasoSmithKiline Multicentre international study of the Genetics of COPD

Respiratory Levy, Robert/ Reid, Graham & Road, Jeremy

Grant 41,820 BC Medical Services Foundation Limb muscle injury in COPD and lung transplantation

Respiratory Ofulue, Felix Contract 350,000 Roche Bioscience Efficacy of matrix metalloproteinase inhibitor in preventing cigarette smoke-induced emphysema.

Respiratory Pare, Peter Grant 288,555 NIH (US): Research Grant 5 R01 HL64068-03

Remodelling of Human Airways in Disease.

Respiratory Pare, Peter Grant 29,979 Ontario Genomics Institute Mapping and isolation of genes influencing severity of disease in cystic fibrosisRespiratory Pare, Peter Grant 1,300 MSFHR: Doctoral Trainee

Research Award # 54(02-1)BM

Contribution of Genes other than CFTR Gene to Disease Severity in Cystic Fibrosis.

Respiratory Pare, Peter Grant 67,766 MR : Operating Grant MOP 37924

Human airway smooth muscle function and bronchial hyperresponsiveness

Respiratory Pare, Peter Grant 64,097 CIHR: Operating Grant MOP 37926

Susceptibility genes for COPD

Respiratory Pare, Peter Grant 506,760 CIHR: Operating Grant GEI-53960

Inflammatory Gene Haplotypes and Susceptibility to Cardiac, Vascular and Pulmonary Disease.

Respiratory Pare, Peter Grant 5,000 CIHR STR 60405 Development Grant: The GREAT (Generous, Research, Education, and Training) PROGRAM: Teams with Themes

Respiratory Pare, Peter Grant 120,000 MSFHR: Distinguished Scholar Award 60(CI-2001):Peter PARE

Molecular and Genetic Mechanisms of Obstructive Lung Disease

Respiratory Pare, Peter Clinical Trial 453,477 GlaxoSmithKline Develop and standardize accurate measurements of emphysema and airway wall dimensions in human lungs

Respiratory Pare, Peter Grant 2,000 Various Sources Physiology Funds





Respiratory Pare, Peter Contract 337,722 Glaxo Wellcome Inc. (NOW GLAXOSMITHKLINE)

A two-year, multi-site family study to identify the genetic determinants associated with susceptibility to chronic obstructive pulmonary disease

Respiratory Road, Jeremy Clinical Trial 87,727 Thera Technologies Inc. TH9507/II/COPD/003

A randomized double-blind, placebo controlled study of the safety and efficacy of two doses of TH9507 on physical performance, lean body mass and peripheral skeletal muscle strength in stable ambulatory COPD subjects

Respiratory Road, Jeremy Clinical Trial 33,738 Byk Canada Inc BY217/M2-107 BY217/M2-107: A Comparison of Treatment with 250 ug Roflumilast vs 500 ug Roflumilast vs Placebo Over 24 Weeks in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Respiratory Road, Jeremy Clinical Trial 18,125 Boehringer Ingelheim (Canada) Ltd.

Protocol 205.252: Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Parallel Group Efficacy & Safety Comparison of 12 Week Treatment of 2 Doses (5ug(W actuations of 2.5) and 10ug (2 actuations of 5 ug) of Tiotropium Inha...

Respiratory Road, Jeremy Grant 18,800 VPR Research Development Fund

Diaphragmatic Responses to Chronic Loading

Respiratory Road, Jeremy Grant 22,500 BC Lung: Project Grant Diaphragmatic Responses to Chronic LoadingRespiratory Ryan, Francis Grant 25,000 University Hospital - Operating

FundsVH Respiratory Sleep Disorders Program - Clinical Trials Coordinator

Respiratory Ryan, Francis Grant 65,000 BC Lung Association BC Lung/VGH Scientist Award: Craniofacial dysmorphism: The obstructive sleep apnea phenotype

Respiratory Sandford, Andrew Grant 90,000 CCFF: Research Genetic Modifiers of Pulmonary Disease Siverity in Cystic FibrosisRespiratory Sandford, Andrew Grant 266,139 CFI: Canada Research Chairs Genetic susceptibility to inflammatory airway diseasesRespiratory Sandford, Andrew Grant 100,000 Canada Research Chair: Tier II

(CIHR) 950-01-2053 Canada Research Chair" Dr. Andrew Sandford

Respiratory Sandford, Andrew Grant 34,222 MRC: Operating Grant MOP 36350

Candidate genes for asthma and atopy in a cohort of at risk infants

Respiratory Sandford, Andrew Grant 103,991 CIHR Operating Grant The role of macrophage protease polymorphisms in the development of emphysemaRespiratory Van Eeden, Stephanus Grant 22,500 BC Lung: Project Grant Monocyte recruitment with pneumoniaRespiratory Van Eeden, Stephanus Grant 22,000 Heighway Fund: Research Heart and blood vessel disease induced by air pollutionRespiratory Van Eeden, Stephanus Grant 37,031 CIHR: Operating Grant MOP

61835Systemic response to atmospheric air pollution

Respiratory Ward, Helen Grant 11,755 Agriculture Canada Canadian Agricultural Injury Surveillance ProgramRespiratory Ward, Helen Agreement 166,585 Worker's Compensation Board of

BC RS2000/01-015Retrospective Cohort Study of Cancer Risks Among Nurses in BC

Respiratory Ward, Helen Agreement 79,900 Worker's Compensation Board of British Columbia

Impact of Western red cedar asthma on work, health and quality of life

Respiratory Ward, Helen Grant 124,030 B.C. Terminal Elevator Operator's Association

Evaluation of the respiratory health of grain elevator workers in the Port of Vancouver

Respiratory Ward, Helen Grant 40,950 CIHR/BC Lung Assn Investigator 40941

Occupational health risks in the Health Care Industry

Respiratory Ward, Helen Grant 42,000 BC Lung/CIHR Investigator Occupational health risks in the health care industryRespiratory Ward, Helen Grant 30,000 BC Lung : Project Grant Growing up on the farm - a protective affect for allergies and asthma?





Respiratory Wilcox, Pearce Grant 30,000 BC Lung: Project Grant Resource utilization study in COPD (RUSIC) - A prospective study to quantify the effects of COPD exacerbation on the health care resource utilization of COPD patients

Respiratory Wilcox, Pearce Clinical Trial 2,000 Boehringer Ingelheim (Canada) Ltd.

Resource utilization study in COPD (RUSIC) - A prospective study to quantify the effects of COPD exacerbation on the health care resource utilization of COPD patients

Respiratory Wilcox, Pearce Grant 4,195 Various SourcesRespiratory Wilcox, Pearce Clinical Trial 2,289 Intermune Pharmaceuticals, Inc. A randomized, double-blind, three-arm phase IIIb study comparing the safety and efficacy of

Interferon gamma-1b alone, interferon gamma 1b with Azathioprine and Azathioprine alone in patients with idiopathic pulmonary fibrosis receiving pre…

Respiratory Wilcox, Pearce Clinical Trial 9,351 Boehringer Ingelheim Pharmaceuticals Inc.

Spriva Assessment of FEV1 (SAFE) The effect of inhaled tiotropium bromide (18mcg once daily) on the change in FEV1 during long-term treatment in patients with COPD. A one-year parallel group, double-blind, randomised, placebo-controlled, st…

Rheumatology Anis, Aslam/ Esdaile, John

Grant 27,920.00 CAN A cost-utility analysis of infliximab plus methotrexate versus methotrexate alone for the treatment of rheumatoid arthritis


Grant 36,120.00 CAN The sensitivity to change and responsiveness of different indirect utility measures: the Health Utilities Index, the SF36, the EuroQol, and a disease-specific measure, the RA Qol questionnaire, in pts with RA


Grant 24,422.00 CAN Cost-effectiveness of anakinra (a new interleukin 1 blocker) compared to standard therapy and infliximab plus methotrexate for the treatment of rheumatoid arthritis

Rheumatology Blocka, Kenneth/ Huang, Simon

Clinical Trial 4,720 Pharmacia Clinical protocol for a double-blind, placebo-controlled, randomized six week comparison study of the efficacy of valdecoxib 20 mg QD and refecoxib 25 mg. QD in relieving the signs and symptoms of osteoarthritis of the knee

Rheumatology Chalmers, Andrew/ Klinkhoff, Alice

Clinical Trial 7,821 Alexion A Phase IIB Randomized, Double-Blind, Placebo-Controlled Study of the Effect of H5G1.1-MAB on Rheumatoid Arthritis Patients with Active Disease Despite Receiving Methotrexate or Leflunomide

Rheumatology Chalmers, Andrew/ Klinkhoff, Alice

Clinical Trial 10,000 Bristol-Meyers Squibb A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of BMS-188667 Administered Intravenously to Subjects with Active Rheumatoid Arthritis With or Without Medical Co-Morbidities Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS) and/or Biologics Approved for RA

Rheumatology Chalmers, Andrew/ Esdaile, John

Clinical Trial 7,650 Fujisawa An open-label, long term study to evaluate the safety of Prograf (tacrolimus) for the treatment of rheumatoid arthritis

Rheumatology Cibere, Jolanda Grant 50,000 CIHR Clinical Scientist Phase IRheumatology Cibere, Jolanda/

Esdaile, JohnGrant 12,662 MPRF Glucosamine sulfate withdrawal study in osteoarthritis

Rheumatology Edworthy, Stephen/ Esdaile, John

Grant 2,500 CAN Interactive learning on the internet for community rheumatologists

Rheumatology Esdaile, John/ Blocka & Lacaille

Clinical Trial 7,313 Merck Frost A Randomized, Double-Blind, Active-comparator-Controlled, parallel Group Study to Evaluate the Safety of Extoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis

Rheumatology Esdaile, John Grant 45,000 Arthritis Society: Clinician Teacher Award

To enhance recruitment of physicians into rheumatology

Rheumatology Esdaile, John Grant 2,500 MSFHR: Doctoral Trainee Research Award 264-POP

Development and Pilot Testing of Novel Intervention to Ensure Optimal Support for Arthritis Patients





Rheumatology Esdaile, John Grant 17,500 Arthritis Society: TAS00/0190,88062

UBC Rheumatic Disease Unit

Rheumatology Esdaile, John/ Cibere, Jolanda

Clinical Trial 52,897 CIHR: Clinician Scientist Award MC1-35439

Double-blind placebo-controlled glucosamine sulfate withdrawal study in osteoarthritis

Rheumatology Esdaile, John/ Lacaille, Klinkhoff & Lehman

Grant 73,600 MRC Randomized, double blind, placebo controlled, multi-centre trial of combination MTX-IM gold in RA

Rheumatology Esdaile, John/ Lacaille & klinkhoff

Grant 72,778 TAS Randomized, double blind, placebo controlled, multi-centre trial of combination MTX-IM gold in RA

Rheumatology Esdaile, John/ Cibere, Liang & Kopec

Grant 101,107 CIHR Development of a model for the diagnosis of early knee osteoarthritis

Rheumatology Esdaile, John/ Tsang, Ian

Grant 10,000 FMSBC Complementary and alternative medicine in arthritis

Rheumatology Esdaile, John/ Cibere, Kopec & Liang

Grant 22,742 CAN Imaging validated model for early diagnosis of Knee OA

Rheumatology Esdaile, John/ Lacaille, Duncan, Backman, Garbuz, Macintyre, Kopec, Liang, & Greidanus

Grant 6,375 CIHR Training Program in arthritis and musculoskeletal diseases

Rheumatology Fortin, Paul/ Cibere & Esdaile

Grant 62,500 CAN Validity and reliability study of osteoarthritis markers

Rheumatology Garbuz, Don/ Esdaile, Anis, Masri, Duncan, Backman, Kopec, Liang & Greidanus

Grant 54,528 TAS A randomized controlled trial of long vs short wait for primary total hip and knee arthroplasty

Rheumatology Gignac, Monique/ Lacaille & Anis

Grant 34,975 CAN Arthritis disability and participation in employment

Rheumatology Huang, Simon/ Blocka, Kenneth

Clinical Trial 3,438 Novartis A 39-week non placebo-controlled extension to a 13-week multicentre randomized double-blind double dummy placebo-controlled parallel trial of 2 doses of COX 189 (200 mg amd 400 mg od) in patients with knee primary osteoarthritis using celecoxib (200 mg od) as a comparator.

Rheumatology Huang, Simon/ Blocka, Kenneth

Clinical Trial 3,643 Novartis A 39-week non-placebo-controlled extension to a 13-week multicentre randomized double-blind double dummy placebo-controlled parallel trial of 2 doses of COX 189 (200 mg and 400 mg od) in patients with knee primary osteoarthritis using celecoxib (200 mg od) as a comparator

Rheumatology Klinkhoff, Alice/ Chalmers, Andrew

Clinical Trial 6,052 Abbott Continuation study of D2E7 in RAA multi-centre continuation of the human anti-TNF antibody D2E7 administered as a subcutaneous injection in patients with rheumatoid arthritis






Clinical Trial 7,500 Amgen Randomized, placebo-controlled, double-blind, multicentre study to evaluate efficacy and safety of Pegylated, recombinant, methionyl human soluble tumor necrosis factor receptor type 1 (PEG sTNG-RI) given twice weekly to subjects with rheumatoid arthritis receiving methotrexate


Clinical Trial 3,060 Amgen Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment with Pegsunercept (PEG sTNF-RI) in subjects with Rheumatoid Arthritis

Rheumatology Klinkhoff, Alice/ Dutz, Jan

Clinical Trial 6,293 Aventis Multicentre, multinational, double-blind, parallel, randomized, placebo controlled study of leflunomide in the treatment of psoriatic arthritis (PsA)

Rheumatology Kopec, Jacek/ Esdaile, John

Grant 39,322 CIHR Physical activity and Osteoarthritis: A case-control study

Rheumatology Kopec, Jacek/Esdaile & Abrahamowicz

Grant 69,250 CAN Multi-level adaptive assessment of health-related quality of life: Integration of item response theory and preference-based measurement

Rheumatology Kopec, Jacek/ Chalmers & Klinkhoff

Grant 52,249 TAS Measuring treatment preference in patients with OA of the hip & knee

Rheumatology Kopec, Jacek/ Cibere, Anis, Badley, & Greidanus

Grant 138,096 CIHR Population-Clinical simulation model of osteoarthritis: development and applications

Rheumatology Lacaille, Diane Grant 50,000 CIHR/TAS New Investigator AwardRheumatology Lacaille, Diane Grant 10,000 VHHSC Scholar AwardRheumatology Lacaille, Diane/

Esdaile, JohnGrant 77,596 CIHR Preventing work loss from inflammatory arthritis: Program development and testing

Rheumatology Lacaille, Diane/ Esdaile, John

Grant 41,805 TAS Preventing work loss from inflammatory arthritis: Program development and testing

Rheumatology Lacaille, Diane/ Esdaile, John

Grant 45,000 CAN Assessing the quality of care for rheumatoid arthritis (RA) at a population level

Rheumatology Lacaille, Diane/ Adam, Paul

Grant 31,667 CAN Self-employment: an alternative to allow individuals with arthritis and musculoskeletal conditions to return to work

Rheumatology Lehman, Allen Grant 6,000 MSFHR Doctoral FellowshipRheumatology Lehman, Allen Grant 20,000 CIHR Doctoral FellowshipRheumatology Lehman, Allen Grant 5,000 CAN Doctoral FellowshipRheumatology Tsang, Ian/Badii Clinical Trial 2,300 Purdue Buprenorphine Trandermal System or Acetaminophen Plus Codein for Poiod Therapy in Patients

with Chronic Low Back Pain

TOTALS CDN 53,222,028$


ubc department of medicine awards by division for … · awards by division for 2002-2003 division...

Documents